WO2008140842A1 - Methods and compositions for heavy metal detoxification - Google Patents

Methods and compositions for heavy metal detoxification Download PDF

Info

Publication number
WO2008140842A1
WO2008140842A1 PCT/US2008/053803 US2008053803W WO2008140842A1 WO 2008140842 A1 WO2008140842 A1 WO 2008140842A1 US 2008053803 W US2008053803 W US 2008053803W WO 2008140842 A1 WO2008140842 A1 WO 2008140842A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydroxy
cyclopent
hydroxy
methylbutanoyl
methylbutyl
Prior art date
Application number
PCT/US2008/053803
Other languages
French (fr)
Inventor
Matthew L. Tripp
Veera Konda
Amy Hall
Anu Desai
Jeffrey S. Bland
Original Assignee
Metaproteomics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaproteomics, Llc filed Critical Metaproteomics, Llc
Priority to CN200880023922A priority Critical patent/CN101687834A/en
Priority to EP08729724A priority patent/EP2152684A4/en
Priority to JP2010508463A priority patent/JP2010526882A/en
Priority to CA002686043A priority patent/CA2686043A1/en
Priority to MX2009012087A priority patent/MX2009012087A/en
Priority to AU2008251756A priority patent/AU2008251756B2/en
Priority to NZ581064A priority patent/NZ581064A/en
Publication of WO2008140842A1 publication Critical patent/WO2008140842A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22Radicals substituted by oxygen atoms
    • C07D309/24Methylol radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/707Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups a keto group being part of a three- to five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/743Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
    • AHUMAN NECESSITIES
    • A62LIFE-SAVING; FIRE-FIGHTING
    • A62DCHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
    • A62D2101/00Harmful chemical substances made harmless, or less harmful, by effecting chemical change
    • A62D2101/20Organic substances
    • A62D2101/24Organic substances containing heavy metals

Definitions

  • the present invention relates generally to compositions and methods to promote heavy metal detoxification in mammals in need. More specifically, the invention relates to the use of spent hops, zinc, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione), and (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) or combinations thereof for heavy metal detoxification in the non-acute state.
  • Heavy metal toxicity can result in damaged or reduced mental and central nervous function, lower energy levels, and damage to blood components, lungs, kidneys, liver, and other vital organs. Furthermore, long term chronic exposure has been attributed to physical, neurological or muscular degenerative processes which appear to mimic muscular dystrophy, multiple sclerosis or Parkinson's or Alzheimer's diseases. Additionally, some heavy metals have been identified as potent mutagens and/or carcinogens.
  • Heavy metal toxicity symptomology is not difficult to recognize.
  • the symptoms usually severe, are commonly associated with a known exposure or ingestion of the metal. Onset of symptoms is usually rapid and can include cramping, nausea, and vomiting; pain; sweating; headaches; difficulty breathing; impaired cognitive, motor, and language skills; mania; and convulsions.
  • Symptoms of chronic exposure are very similar to symptoms of other health conditions and often develop slowly over months or even years.
  • the symptoms of toxicity resulting from chronic exposure are much more difficult to associate with their cause.
  • a further problem in identifying chronic exposure occurs because the symptoms of chronic exposure may abate from time to time, leading the afflicted individual to postpone seeking treatment, believing the symptoms are related to something other than metal toxicity.
  • the most commonly encountered toxic metals include aluminum, arsenic, cadmium, iron, lead, and mercury.
  • Arsenic and lead poisonings tend to be the most common due to their wide use in smelting processes, chemical and glass manufacture, or pesticide use (arsenic) while lead exposure can occur from pipes, paint, batteries, and PVC plastics.
  • Target organs for arsenic toxicity include blood, kidneys and digestive, skin and central nervous systems while lead most commonly targets bones, brain, blood, kidneys and the thyroid.
  • Cadmium toxicity usually targets the brain and kidney resulting from environmental exposures from PVC pipes, batteries and paint pigments.
  • Xenobiotic metabolizing enzymes play a major role in regulating the toxic, oxidative damaging, mutagenic, and neoplastic effects of chemical carcinogens.
  • Phase II detoxification enzymes such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQOl) activity result in protection against toxicity and chemical carcinogenesis, especially during the initiation phase.
  • GSTs glutathione S-transferases
  • NQOl NADPH quinone reductase
  • NQOl is a flavoprotein that catalyzes two electron reduction of quinones and nitrogen oxides (Riley, RJ. and P.
  • ARE exacting transcriptional enhancer
  • electrophile response element Friling, R. S., et al., Proc Natl Acad Sci U S A, 87(16): 6258-62, 1990. It has been shown that the transcription factor Nrf-2 positively regulates the ARE-mediated expression of the phase II detoxification enzyme genes. Itoh et al.
  • Nrf-2 is a general regulator of the phase II enzyme genes in response to electrophiles and reactive oxygens. More recently, the general regulatory mechanism underlying the electrophile counterattack response has been demonstrated in which electrophilic agents alter the interaction of Nrf-2 with its repressor protein (Keap-1), thereby liberating Nrf-2 activity from repression by Keap-1, culminating in the induction of the phase II enzyme genes and antioxidative stress protein genes via AREs (Itoh, K., et al., Genes Dev, 13(1): 76-86, 1999).
  • AREs Itoh, K., et al., Genes Dev, 13(1): 76-86, 1999.
  • Nrf-2 may involve modification of either one of these proteins and could be achieved by direct or indirect mechanisms.
  • Nrf-2 can be phosphorylated by components of the MAP kinase cascade (Yu, R., et al., J Biol Chem, 274(39): 27545-52, 1999), which could result in its dissociation.
  • Heme oxygenase- 1 an essential enzyme in heme catabolism
  • MT-2A metallothionein IIA
  • Both proteins are considered to be involved in the defense system against metal toxicity.
  • Heme oxygenase is regulated by both Nrf-2 and MTF-I transcriptional factors through the activation of ARE and MRE binding sites on heme oxygenase gene.
  • the present invention relates to compositions and methods to promote heavy metal detoxification under non-acute conditions in mammals. More specifically, the invention relates to the use of spent hops, zinc, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5- dione), and (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) or combinations thereof for heavy metal detoxification in the non-acute state.
  • a first embodiment of the invention describes compositions for promoting heavy metal detoxification in a mammal in need.
  • the compositions comprise a therapeutically effective amount of at least two members selected from the group consisting of spent hops; 1 ,7- Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; zinc; and 3-(2-(Decahydro-6- hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one.
  • Methods for promoting heavy metal detoxification in a mammal in need are described in a second embodiment.
  • the methods entail administering to the mammal a composition comprising a therapeutically effective amount of at least two members selected from the group consisting of spent hops; l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta- l,6-diene-3,5-dione; zinc; and 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
  • a further embodiment of the invention describes a composition comprising: from about 0.10 to about 10.00 grams of spent hops; from about 5 to about 1200 mg of 1,7-Bis(4- hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; from about 0.10 to about 24 mg of zinc; and from about 5 to about 1200 mg of 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a- dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
  • Another embodiment describes methods for promoting heavy metal detoxification in a mammal in need.
  • the method utilizes a composition comprising: from about 0.10 to about 10.00 grams of spent hops; from about 5 to about 1200 mg of 1,7-Bis(4- hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; from about 0.10 to about 24 mg of zinc; and from about 5 to about 1200 mg of 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a- dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
  • a method for promoting heavy metal detoxification in a mammal in need comprises administering to the mammal a composition comprising a therapeutically effective amount of spent hops.
  • Figure 1 is a graphic representation of the chemical structure of 1,7-Bis(4- hydroxy-3-methoxyphenyl)hepta- 1 ,6-diene-3,5-dione.
  • Figure 2 is a graphic representation of the chemical structure of 3-(2-(Decahydro-
  • Figure 3 depicts a Western blot analysis of Nrf-2 in the nuclear fraction of HepG2 cells treated for 4 hours with the indicated test compound.
  • Formula DF-SH is the combination of spent hops, 7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione (curcumin), 3-(2- (Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one (andrographis), Rho dyhdro- isoalpha acids (RIAA) mixture and Zn (525:30:30:4:1).
  • Figure 4 depicts a Western blot analysis of Nrf-2 in the nuclear fraction of HepG2 cells treated for 4 hours with the indicated test compound.
  • Formula 3 Components is the combination of Isoalpha acid (IAA), 7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5- dione (curcumin), and 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one (andrographis), (1 :1 :1).
  • Figure 5 graphically depicts the increased induction of metal lothionein mRNA levels in volunteers following administration of a test formulation comprising (per tablet): zinc (1.667 mg); 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one (50 mg); l,7-Bis(4-hydroxy- 3-methoxyphenyl)hepta-l,6-diene-3,5-dione (50 mg); spent hops (875 mg) and a Rho dihydro- isoalpha acid mixture (6.667 mg).
  • Figure 6 graphically depicts the increased induction of metallothionein mRNA levels measured using alternative primers in volunteers following administration of a test formulation comprising (per tablet): zinc (1.667 mg); 3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one (50 mg); l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione (50 mg); spent hops (875 mg) and a Rho dihydro-isoalpha acid mixture (6.667 mg).
  • Figure 7 graphically depicts the effects of test formulation on urinary excretion of clinically important metals. * denotes a detectable increase in excretion.
  • Figure 8 graphically depicts the effects of test formulation on urinary excretion of non-clinically important metals.
  • Figure 9 graphically depicts the effects of test formulation on urinary excretion of nutrients. * denotes a detectable increase in excretion.
  • the present invention relates to compositions and methods to promote heavy metal detoxification under non-acute conditions in mammals. More specifically, the invention relates to the use of spent hops, zinc, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5- dione), and (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) or combinations thereof for heavy metal detoxification in the non-acute state.
  • variable As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range.
  • the variable can be equal to any integer value of the numerical range, including the end-points of the range.
  • the variable can be equal to any real value of the numerical range, including the end-points of the range.
  • a variable which is described as having values between 0 and 2 can be 0, 1 or 2 for variables which are inherently discrete, and can be 0.0, 0.1, 0.01, 0.001, or any other real value for variables which are inherently continuous.
  • a first embodiment of the invention describes compositions for promoting heavy metal detoxification in a mammal in need, where the compositions comprise a therapeutically effective amount of at least two members selected from the group consisting of spent hops; 1 ,7- Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; zinc; and 3-(2-(Decahydro-6- hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one.
  • compositions further comprise a compound selected from the group consisting of (4 1 S',55)-3,4-dihydroxy-4-[(LS)-hydroxy-4-methylpent-3-en- l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4R,5R)-3,4- dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en- l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2- (2-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,
  • compositions further comprise a compound selected from the group consisting of 4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5- (3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4R,5S)-3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4/?,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyI)cycl
  • compositions further comprising a compound selected from the group consisting of (4S',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methy lbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydro xy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(lS)-l- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2
  • compositions further comprise a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.
  • a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.
  • the compositions further comprise one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.
  • promoting heavy metal detoxification refers to inducing detoxification enzyme production, augmenting the enzymatic activity of existing detoxification enzymes, or inhibiting the inhibitors of the detoxification enzymes.
  • detoxification enzymes include alcohol sulphotransferase, amine N- methyltransferase, amine O-sulphotransferase, arylamine N-acetyltransferase (NAT2), catechol O-methyltransferase, cysteine conjugate ⁇ -lyase, cysteine N-acetyltransferase, glycine acyltransferase, glutamate acyltransferase, glutathione S-transferases (GST), heme oxygenase- 1, histamine N-methyltransferase, microsomal epoxide hydrolase (mEH), metallothioneins, NAD(P)H: quinone
  • the terms “comprise(s)” and “comprising” are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases “having at least” or “including at least”.
  • the term “comprising” means that the process includes at least the recited steps, but may include additional steps.
  • the term “comprising” means that the compound or composition includes at least the recited features or components, but may also include additional features or components.
  • compounds may be identified either by their chemical structure, chemical name, or common name. When the chemical structure and chemical or common name conflict, the chemical structure is determinative of the identity of the compound.
  • the compounds described herein may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers or diastereomers.
  • the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the illustrated or identified compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures.
  • Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan.
  • the compounds may also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated or identified compounds.
  • the compounds described also encompass isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature.
  • isotopes that may be incorporated into the compounds of the invention include, but are not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, etc.
  • Compounds may exist in unsolvated forms as well as solvated forms, including hydrated forms and as N-oxides. In general, compounds may be hydrated, solvated or N-oxides. Certain compounds may exist in multiple crystalline or amorphous forms.
  • congeners, analogs, hydrolysis products, metabolites and precursor or prodrugs of the compound In general, unless otherwise indicated, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention.
  • Compounds according to the invention may be present as salts.
  • pharmaceutically acceptable salts of the compounds are contemplated.
  • a “pharmaceutically acceptable salt” of the invention is a combination of a compound of the invention and either an acid or a base that forms a salt (such as, for example, the magnesium salt, denoted herein as “Mg” or “Mag”) with the compound and is tolerated by a subject under therapeutic conditions.
  • a pharmaceutically acceptable salt of a compound of the invention will have a therapeutic index (the ratio of the lowest toxic dose to the lowest therapeutically effective dose) of 1 or greater. The person skilled in the art will recognize that the lowest therapeutically effective dose will vary from subject to subject and from indication to indication, and will thus adjust accordingly.
  • compositions according to the invention are optionally formulated in a pharmaceutically acceptable vehicle with any of the well known pharmaceutically acceptable carriers, including diluents and excipients (see Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, Mack Publishing Co., Easton, PA 1990 and Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins, 1995). While the type of pharmaceutically acceptable carrier/vehicle employed in generating the compositions of the invention will vary depending upon the mode of administration of the composition to a mammal, generally pharmaceutically acceptable carriers are physiologically inert and non-toxic.
  • Formulations of compositions according to the invention may contain more than one type of compound of the invention), as well any other pharmacologically active ingredient useful for the treatment of the symptom/condition being treated.
  • pharmaceutically acceptable is used in the sense of being compatible with the other ingredients of the compositions and not deleterious to the recipient thereof.
  • hop refers to plant cones of the genus Humulus which contain a bitter aromatic oil which is used in the brewing industry to prevent bacterial action and add the characteristic bitter taste to beer. More preferably, the hops used are derived from Humulus lupulus.
  • therapeutically effective amount is used to denote treatments at amounts of the compositions effective to achieve the therapeutic result sought.
  • therapeutically effective amount may be lowered or increased by fine tuning and/or by administering more than one composition of the invention, or by administering a composition of the invention with another composition or compound. See, for example, Meiner, C. L., “Clinical Trials: Design, Conduct, and Analysis,” Monographs in Epidemiology and Biostatistics, Vol. 8 Oxford University Press, USA (1986).
  • the invention therefore provides a method to tailor the administration/treatment to the particular exigencies specific to a given mammal.
  • therapeutically effective amounts may be easily determined for example empirically by starting at relatively low amounts and by step-wise increments with concurrent evaluation of beneficial effect.
  • solvents refers to the solid and hydrophilic residue resulting from (1) exposing a hops plant product to a solvent, (2) separating the solvent from the hops plant products, and (3) eliminating the solvent.
  • Representative solvents can include CO2, water, organic solvents (e.g., alcohols) or mixtures thereof.
  • l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione is presented graphically in Figure 1.
  • "l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene- 3,5-dione” refers to curcumin, a yellow pigmented fraction isolated from the rhizomes of Curcuma longa.
  • the curcuminoids are considered the important active ingredients and are believed to be responsible for the biological activity of Curcuma longa. Though their major activity is anti-inflammatory, curcuminoids have been reported to possess antioxidant, antiallergic, wound healing, antispasmodic, antibacterial, antifungal and antitumor activity as well.
  • Diterpene lactone species such as andrographolide are commonly found in plants and are used for their anti-inflammatory properties. Their mechanism of action is believed to be due (i) to the inhibition of histamine release from mast cells or (ii) to the inhibition of lipoxygenase and cyclooxygenase activity thereby reducing the synthesis of inflammatory factors produced during the arachidonic acid cascade.
  • reduced isoalpha acid refers to alpha acids isolated from hops plant product and subsequently have been isomerized and reduced, including cis and trans forms.
  • reduced isoalpha acids include without limitation dihydro- isoalpha acids, more specifically Rho dihydro-isoalpha acids (Table 1), tetra-hydroisoalpha acid (Table 2), and hexa-hydroisoalpha acids (Table 3), and their derivatives.
  • Rho refers to those reduced isoalpha acids wherein the reduction is a reduction of the carbonyl group in the 4- methyl-3-pentenoyl side chain.
  • the terms "derivatives" or a matter “derived from” refer to a chemical substance related structurally to another substance and theoretically obtainable from it, i.e. a substance that can be made from another substance.
  • Derivatives can include compounds obtained via a chemical reaction or de novo chemical syntheses. See Verzele, M. and De Keukeleire, D., Developments in Food Science 27: Chemistry and Analysis of Hop and Beer Bitter Acids, Elsevier Science Pub. Co., 1991, New York, USA, herein incorporated by reference in its entirety, for a detailed discussion of hops chemistry.
  • a second embodiment of the invention describes methods for promoting heavy metal detoxification in a mammal, where the methods utilize compositions which comprise a therapeutically effective amount of at least two members selected from the group consisting of spent hops; l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; zinc; and 3-(2- (Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
  • compositions of the method further comprise a compound selected from the group consisting of (4.S',55)-3,4-dihydroxy-4-[(15)- hydroxy-4-methylpent-3-en-l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2- en- 1 -one; (4i?,5i?)-3,4-dihydroxy-4-[( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4- [(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-l- yl)cyclopent-2-
  • compositions of the method further comprise a compound selected from the group consisting of 4i?,5.S)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4R,5S)-3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-
  • compositions of the method further comprising a compound selected from the group consisting of (4S,55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(l S)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S,5S)- 3,4-dihydroxy-4-[( IS)-I -hydroxy ⁇ -methylpenty ⁇ -CS-methylbutanoyO-S-CS- methylbutyl)cyclopent-2-en-l-one; (45',5 ⁇ S)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2- (S-r
  • compositions used further comprise a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.
  • compositions of the methods further comprise one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.
  • the methods of the present invention are intended for use with any mammal that may experience the benefits of the methods of the invention. Foremost among such mammals are humans, although the invention is not intended to be so limited, and is applicable to veterinary uses.
  • "mammals" or “mammals in need” include humans as well as non-human mammals, particularly domesticated animals including, without limitation, cats, dogs, and horses.
  • a composition comprising: from about 0.10 to about 10.00 grams of spent hops; from about 5 to about 1200 mg of l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5- dione; from about 0.10 to about 24 mg of zinc; and from about 5 to about 1200 mg of 3-(2- (Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one is described in a third embodiment of the invention while a further embodiment of the invention describes methods for promoting heavy metal detoxification in a mammal, where the methods utilize compositions comprising from about 0.10 to about 10.00 grams of spent hops; from about 5 to about 1200 mg of l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; from
  • a further embodiment of the invention describes methods for promoting heavy metal detoxification in a mammal utilizing a composition comprising a therapeutically effective amount of spent hops.
  • Test Materials All test compounds were supplied by Metagenics (San Clemente,
  • Test compounds were prepared in dimethyl sufoxide (DMSO) and stored at -20 0 C.
  • DMSO dimethyl sufoxide
  • Sulforaphane, glutathione and 1-Chloro 2, 4-dinitro benzene (CDNB) were purchased from Sigma Chemicals (St.Louis, MO). All other general chemicals were analytical grade.
  • Japan Health Science Foundation (Tokyo, Japan). Cells were maintained in log phase in DMEM media supplemented with 5% heat inactivated FBS, 100 IU penicillin, and 100 ⁇ g/ml streptomycin.
  • the human liver cell line HepG2 was purchased from ATCC (Manassas, VA). Cells were maintained in log phase in MEM media supplemented with 10% heat inactivated FBS, 100 IU penicillin, and 100 ⁇ g/ml streptomycin.
  • Enzymatic activity in RL-34 cells were subcultured in 6-well plates at a density of 3 x 10 5 cells per well. The following day test compounds in DMSO were added at a final 0.1% DMSO concentration. The cells were incubated with test compound for 2 days in a humidified incubator at 37°C after which the cells were lysed and assayed for enzyme activity. Following treatment with test compounds, cells were washed twice with 0.5 ml PBS and all residual liquid was removed. To lyse the cells, 150 ⁇ L Buffer D (0.8% digitonin in 2 mM EDTA) was added to each well and incubated for 15 minutes at room temperature.
  • Buffer D (0.8% digitonin in 2 mM EDTA
  • the cell lysate was centrifuged for 10 minutes at 10,000 rpm. The supernatant containing the cell lysate was transferred into a 96-well plate. Protein determination was performed using the Bicinchoninic Acid Kit (Sigma, St. Louis, MO). Equal protein concentrations were used in all enzyme activity assays.
  • GST activity assay - Cell lysate (20 ⁇ L) containing the GST enzyme was added to each well of a UV flat bottom 96 well microtiter plate.
  • Reaction buffer was added (300 ⁇ L) to each well to achieve a final concentration of 8 mM glutathione and 3.2 mM CDNB in 100 mM KPO 4 .
  • the enzymatic conversion of CDNB was measured at 340 nm over three minutes to determine a rate of GST activity (Apati, P., et al., J Pharm Pharmacol, 58(2): 251-6, 2006, and Habig, W.H., MJ. Pabst, and W.B. Jakoby, J Biol Chem., 249: 7130-9, 1974).
  • NADPH quinone oxido reductase assay (NQOl) - To assay NQOl activity, 20 ⁇ L of cell lysate containing the NQOl enzyme was added to each well of a flat bottom 96 well microtiter plate. Reaction buffer was added (200 ⁇ L) to each well to achieve a final concentration of 25 mM Tris-HCl, pH 7.4, 5 ⁇ M FAD, 1 mM G6P, 30 ⁇ M NADP, 2 U/ml G6PDH, 0.06% BSA, 725 ⁇ M MTT and 50 ⁇ M menadione.
  • the reduction of MTT at 610 nm was measured after three minutes to determine the induction of NQOl activity (Feng, R., et al., J Biol Chem, 280(30): 27888-95, 2005. and Prochaska, HJ. and A.B. Santamaria, Anal Biochem., 169: 328-36, 1988).
  • the induction of NQOl activity was determined as the ratio of treated over vehicle control.
  • Luciferase activity Two days after the transfection, cells were washed with phosphate-buffered saline and lysed in passive lysis buffer from the Dual Luciferase reporter assay system per the manufacturer's protocol (Promega). First, the cell lysate was assayed for the firefly luciferase activity using 100 ⁇ l of the substrate LARII. Then 100 ⁇ l of the STOP & GLO reagent was added to quench the firefly luciferase activity and activate the Renilla luciferase, which was also measured.
  • the assays were carried out in a PerkinElmer luminometer, and the relative luciferase activity was calculated as follows: 100,000/activity of Renilla luciferase (in units) 3 activity of firefly luciferase (in units). Each set of transfections was repeated three times.
  • test compounds in DMSO were added at a final 0.1% DMSO concentration.
  • the cells were incubated with test compound for 8 hours in a humidified incubator at 37°C.
  • the mRNA was then purified for gene expression analysis using TRI reagent (Sigma Chemicals) according to the manufacture's instructions.
  • TRI reagent Sigma Chemicals
  • the cDNA template was generated for use in the QPCR analysis. This was performed with the Omniscript RT kit (Qiagen, Valencia, CA) at 37 0 C for 60 min in a Techgene thermocycler (Techne, Burlington, NJ) to yield a 20 ⁇ L reaction with 2 ⁇ g starting mRNA.
  • the blinded samples were sent to Dr.
  • Enzymatic activity - Sulforaphane is a known activator of Nrf-2 and was used as a control in the enzymatic activity assays. According to the convention of the scientific literature, 20% induction of activity by test compounds over DMSO control is considered active.
  • GST activity (Table 4) was induced > 20% by Sulforaphane (3 ⁇ g/ml), Andrographis (25 ⁇ g/ml), Xanthohumol (1 ⁇ g/ml), Prune (20 ⁇ g/ml), Withania (20 ⁇ g/ml), Osteosine (20 ⁇ g/ml), MCHA (20 ⁇ g/ml), and Arthred Porcine (20 ⁇ g/ml) in RL-34 cell line.
  • NQOl enzymatic activity (Table 5) was induced > 20% by (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin) (5 ⁇ g/ml), (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) (andrographis) (25 ⁇ g/ml), Xanthohumol (1 ⁇ g/ml), Sulforaphane (3 ⁇ g/ml), Withania (20 ⁇ g/ml), I3C (25 ⁇ g/ml), Resveratrol (20 ⁇ g/ml), Milk Thistle (25 ⁇ g/ml), IAA (5 ⁇ g/ml), Pomegranite (25 ⁇ g/ml), Parthenolide (20
  • Formula DF-SH is the combination of spent hops, (l,7-Bis(4-hydroxy-3- methoxyphenyl)hepta- 1 ,6-diene-3,5-dione) (curcumin), (3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one) (andrographis), Rho Isoalpha acid and Zn (525:30:30:4:1) Table 5 Screening of test compounds for NQO-I enzyme activity in the RL-34 cell line
  • Formula DF-SH is the combination of spent hops, (l,7-Bis(4-hydroxy-3- methoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin), (3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one) (andrographis), Rho Isoalpha acid and Zn (525:30:30:4:1) [0078] HO-I Transcriptional activation - Heme oxygenase is regulated by both Nrf-2 and MTF-I transcriptional factors through the activation of ARE and MRE binding sites on heme oxygenase gene.
  • Test compounds (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene- 3,5-dione) (curcumin), xanthohumol, (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a- dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) (andrographis) extract, sulforaphane, IAA, oleanolic acid, green tea catechins, milk thistle, terminalin, ZnCl 2 , garlic, amla fruit extract and cinnamon ground induced the expression of heme oxygenase promoter activity.
  • phase II increased phase II and HMOXl, but not MT.
  • Test compounds that increased > 20% (in rank order) phase II include andrographis, IAA and curcumin;
  • HMOXl include curcumin, andrographis, fucus mesh, gymnogongrus, IAA, and xanthohumol;
  • MT include oleanolic acid, fucus mesh, xanthohumol and gymnogongrus.
  • 3C formula is the combination of equal ratios of IAA, (l,7-Bis(4-hydroxy-3- rnethoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin), and (3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one) (andrographis).
  • SH formula is the combination of spent hops, Rho Isoalpha acid, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin), (3-(2-(Decahydro- 6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one) (andrographis), and zinc (525:4:30:30:1).
  • the gray shading indicates only one replicate
  • Nrf-2 Translocation The translocation of Nrf-2 from the cytoplasm to the nucleus has been shown to occur with treatment of xenobiotics and antioxidants (Chan, J. Y. and M. Kwong, Biochim Biophys Acta, 1517(1): 19-26, 2000, and Chan, K., et al., Proc Natl Acad Sci U S A, 93(24): 13943-8, 1996). As seen in Figures 3 and 4, Nrf-2 was observed in the nuclear fraction of HepG2 cells treated with test compound after 4 hours. As a control, sulforaphane displayed a dramatic increase in Nrf-2 nuclear translocation.
  • RNAlater (Ambion, Austin, TX). RNA extractions were performed with the RiboPure Blood RNA Isolation Kit (Ambion, Austin, TX) according to the manufacturers specifications. RNA was quantified with a Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, DE).
  • Reverse Transcriptase Assays - RNA was converted to first strand cDNA by use of the RETROscript First Strand Synthesis Kit (Ambion, Austin, TX) and primed with oligo-dT according to the manufacturers specifications.
  • Primers and Probes A Taqman gene expression assay to quantify GAPDH expression, which was used as an endogenous control, was obtained from Applied Biosystems (Foster City, CA; assay Hs99999905_ml). Primers and probes for Taqman-based assays targeting human metallothioneins have been previously described (Aydemir TB, Blanchard RK, and Cousins RJ, 2006. Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. Proc. Natl. Acad. Sci. USA 103, 1699-1704). Forward and reverse primers, and HPLC -purified Taqman probes labeled with 5'-FAM and 3'-TAMRA, were obtained from Operon Biotechnologies, Inc (Huntsville, AL).
  • hMTl 2-F 5'- GCACCTCCTGCAAGAAAAGCT hMTl,2-R 5'- GCAGCCTTGGGCACACTT hMT 1 ,2-T 5 ' - FAM C AC AGCCC AC AGGGC AGC AGG TAMRA hMTl, 2AIt-F 5'- GCACCTCCTGCAAGAAGAGCT hMTl, 2AIt-R 5'- GCAGCCCTGGGCACACTT hMTl, 2AIt-T 5'- FAM ACAGCCCACAGGACAGCAGG
  • First strand cDNA was synthesized as described above.
  • the cDNA equivalent of 20 ng starting RNA was then included in qPCR reactions.
  • Reactions to detect metallothionein expression contained IX Taqman Master Mix (Applied Biosystems, Foster City, CA), forward and reverse primers at 400 nM, and Taqman probe at 200 nM.
  • Reactions to detect GAPDH expression contained IX Taqman Master Mix (Applied Biosystems) and IX gene- specific assay reagents as recommended by the manufacturer (Applied Biosystems). All reactions were run in triplicate. Reactions that did not contain template cDNA were included as negative controls.
  • the cDNA equivalent of 100 ng starting RNA was included in qPCRs with the other conditions as described above. A reference sample was included in both assays to allow cross-assay comparison.
  • the AmpliTaq Gold polymerase was activated at 95 0 C for 10 min followed by 40 cycles consisting of denaturation for 15 seconds at 95 0 C and annealing and extension for 60 seconds at 6O 0 C.
  • Results are depicted graphically in Figures 5 and 6 demonstrating the efficacy of the intervention in increasing measures of hepatic detoxification metallothionein mRNA levels.

Abstract

Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione s-transferases (GSTs), and NADPH quinone reductase (NQOl) activity.

Description

UNITED STATES PATENT APPLICATION for
METHODS AND COMPOSITIONS FOR HEAVY METAL DETOXIFICATION
METHODS AND COMPOSITIONS FOR HEAVY METAL DETOXIFICATION
CROSS-REFERENCE TO RELATED APPLICATIONS
[001] This patent application claims priority to U.S. provisional application Ser. No.
60/917,425 filed on May 11, 2007.
BACKGROUND OF THE INVENTION
Field of the Invention
[002] The present invention relates generally to compositions and methods to promote heavy metal detoxification in mammals in need. More specifically, the invention relates to the use of spent hops, zinc, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione), and (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) or combinations thereof for heavy metal detoxification in the non-acute state.
Description of the Related Art
[003] There are numerous metals which may pose health concerns due to residential or occupational exposure. Of these; antimony, arsenic, bismuth, cadmium, cerium, chromium, cobalt, copper, gallium, gold, iron, lead, manganese, mercury, nickel, platinum, silver, tellurium, thallium, tin, uranium, vanadium, and zinc are considered the most problematic. Many of these elements are common to our diet and environment and are actually necessary for maintaining good health. However, exposure to larger amounts may result in acute or chronic toxicity.
[004] Heavy metal toxicity can result in damaged or reduced mental and central nervous function, lower energy levels, and damage to blood components, lungs, kidneys, liver, and other vital organs. Furthermore, long term chronic exposure has been attributed to physical, neurological or muscular degenerative processes which appear to mimic muscular dystrophy, multiple sclerosis or Parkinson's or Alzheimer's diseases. Additionally, some heavy metals have been identified as potent mutagens and/or carcinogens.
[005] Heavy metal toxicity symptomology is not difficult to recognize. The symptoms, usually severe, are commonly associated with a known exposure or ingestion of the metal. Onset of symptoms is usually rapid and can include cramping, nausea, and vomiting; pain; sweating; headaches; difficulty breathing; impaired cognitive, motor, and language skills; mania; and convulsions.
[006] Symptoms of chronic exposure are very similar to symptoms of other health conditions and often develop slowly over months or even years. However, the symptoms of toxicity resulting from chronic exposure (impaired cognitive, motor, and language skills; learning difficulties; nervousness and emotional instability; and insomnia, nausea, lethargy, and feeling ill) while easily recognized are much more difficult to associate with their cause. A further problem in identifying chronic exposure occurs because the symptoms of chronic exposure may abate from time to time, leading the afflicted individual to postpone seeking treatment, believing the symptoms are related to something other than metal toxicity.
[007] The most commonly encountered toxic metals include aluminum, arsenic, cadmium, iron, lead, and mercury. Arsenic and lead poisonings tend to be the most common due to their wide use in smelting processes, chemical and glass manufacture, or pesticide use (arsenic) while lead exposure can occur from pipes, paint, batteries, and PVC plastics. Target organs for arsenic toxicity include blood, kidneys and digestive, skin and central nervous systems while lead most commonly targets bones, brain, blood, kidneys and the thyroid.
[008] Cadmium toxicity usually targets the brain and kidney resulting from environmental exposures from PVC pipes, batteries and paint pigments.
[009] Aluminum, although not a "heavy" metal per se, has been associated with neurotoxicity (Halatek T, et al., J Environ Sci Health A Tox Hazard Subst Environ Eng. 43(2): 118-24, 2008), Alzheimer's disease (Prolo P., et al., Bioinformation. 2007 2(l):24-7, 2007),; Molloy, DW., et al., J Toxicol Environ Health A. 70(23):2011-9, 2007), and cell death (Satoh E., et al., Biol Pharm Bull. 30(8): 1390-4, 2007). [0010] Some heavy metals have been identified as potent mutagens and/or carcinogens.
These metals have been implicated in apoptosis and cell growth regulation, nuclear transcription regulation and effecting various signal transduction pathways. These metals have also been identified as possessing activity effecting gene expression, carcinogenesis, mutagenesis, and cytotoxicity, as well as in free radical generation. For a review, see Wang S. and Shi X., MoI Cell Biochem 222; 3 - 9, 2001.
[0011] Xenobiotic metabolizing enzymes play a major role in regulating the toxic, oxidative damaging, mutagenic, and neoplastic effects of chemical carcinogens. Mounting evidence has indicated that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQOl) activity result in protection against toxicity and chemical carcinogenesis, especially during the initiation phase. NQOl is a flavoprotein that catalyzes two electron reduction of quinones and nitrogen oxides (Riley, RJ. and P. Workman, Biochem Pharmacol, 43(8): 1657-69, 1992 and Ross, D., et al., Cancer Metastasis Rev, 12(2): 83-101, 1993). Although the major function of this protein may be to reduce the formation of reactive oxygen species by decreasing one electron reduction and the associated redox cycling, it also plays a role in activation of some anticancer drugs and cancer prevention (Begleiter, A., et al., Cancer Lett, 45(3): 173-6, 1989 and Begleiter, A., et al., Oncol Res, 9(6-7): 371-82, 1997) Recent studies suggest that NQOl may also be involved in regulation of the transcription factor p53 and apoptosis (Asher, G., et al., Proc Natl Acad Sci U S A, 98(3): 1188-93, 2001 and Long, D.J., 2nd, et al., Cancer Res, 62(11): 3030-6, 2002).
[0012] The transcriptional activation of the phase II enzymes has been traced to a exacting transcriptional enhancer called ARE (Rushmore, T.H., et al., Proc Natl Acad Sci U S A, 87(10): 3826-30, 1990), or alternatively, the electrophile response element (Friling, R. S., et al., Proc Natl Acad Sci U S A, 87(16): 6258-62, 1990). It has been shown that the transcription factor Nrf-2 positively regulates the ARE-mediated expression of the phase II detoxification enzyme genes. Itoh et al. (Biochem Biophys Res Commun, 236(2): 313-22, 1997) have recently established by gene-targeted disruption in mice that Nrf-2 is a general regulator of the phase II enzyme genes in response to electrophiles and reactive oxygens. More recently, the general regulatory mechanism underlying the electrophile counterattack response has been demonstrated in which electrophilic agents alter the interaction of Nrf-2 with its repressor protein (Keap-1), thereby liberating Nrf-2 activity from repression by Keap-1, culminating in the induction of the phase II enzyme genes and antioxidative stress protein genes via AREs (Itoh, K., et al., Genes Dev, 13(1): 76-86, 1999).
[0013] It has been suggested that the dissociation of Nrf-2 from Keap-1 may involve modification of either one of these proteins and could be achieved by direct or indirect mechanisms. For example, Nrf-2 can be phosphorylated by components of the MAP kinase cascade (Yu, R., et al., J Biol Chem, 274(39): 27545-52, 1999), which could result in its dissociation. On the other hand, Dinkova-Kostova et al. (Dinkova-Kostova, A.T., et al., Proc Natl Acad Sci U S A, 98(6): 3404-9, 2001) have provided an alternative possibility that the dissociation of this complex may be potentiated by the direct interaction of electrophilic agents with reactive thiol residues in either of the two proteins. This hypothesis is supported by the strong relationship between the potency of the agents as inducers of the gene expression through the ARE and their rate of reaction with sulfhydryl groups. This mechanism implies that the inducing agent will become covalently bound either to Keap-1 or Nrf-2.
[0014] Heme oxygenase- 1 (HO-I) an essential enzyme in heme catabolism, and metallothionein IIA (MT-2A), a small metal-binding protein with clusters of cysteins, are induced in HeLa cells following the treatment with cadmium or zinc. Both proteins are considered to be involved in the defense system against metal toxicity. Heme oxygenase is regulated by both Nrf-2 and MTF-I transcriptional factors through the activation of ARE and MRE binding sites on heme oxygenase gene.
[0015] By and large, medical research has been directed to acute instances of metal toxin exposure where detoxification and removal of the toxic substance must be accomplished rapidly insofar as the continued presence of the metal toxin places the patient in a true life or death situation. The most common detoxification treatments for metal toxicity include chemical inactivation, metabolic detoxification, or, for example, chelation.
[0016] Currently, these treatments are considered neither appropriate nor indicated for low level toxin exposures, thereby creating a pressing need for safe and effective methods to detoxify individuals with sub-acute metal toxin exposures before toxin build up reaches the requisite level necessitating the more extreme measures described above. The inventors have identified a number of compounds having a history of safety which modulate the activity of key detoxification enzymes and promote toxin removal from the body. The invention described herein teaches enhancement or inducement of detoxification enzyme systems for sub-acute toxin exposures through modulation of key detoxification enzymes and concomitant administration of additional detoxifying and nutritional agents
SUMMARY OF THE INVENTION
[0017] The present invention relates to compositions and methods to promote heavy metal detoxification under non-acute conditions in mammals. More specifically, the invention relates to the use of spent hops, zinc, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5- dione), and (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) or combinations thereof for heavy metal detoxification in the non-acute state.
[0018] A first embodiment of the invention describes compositions for promoting heavy metal detoxification in a mammal in need. Here the compositions comprise a therapeutically effective amount of at least two members selected from the group consisting of spent hops; 1 ,7- Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; zinc; and 3-(2-(Decahydro-6- hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one.
[0019] Methods for promoting heavy metal detoxification in a mammal in need are described in a second embodiment. In this embodiment the methods entail administering to the mammal a composition comprising a therapeutically effective amount of at least two members selected from the group consisting of spent hops; l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta- l,6-diene-3,5-dione; zinc; and 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
[0020] A further embodiment of the invention describes a composition comprising: from about 0.10 to about 10.00 grams of spent hops; from about 5 to about 1200 mg of 1,7-Bis(4- hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; from about 0.10 to about 24 mg of zinc; and from about 5 to about 1200 mg of 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a- dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
[0021] Another embodiment describes methods for promoting heavy metal detoxification in a mammal in need. In this embodiment the method utilizes a composition comprising: from about 0.10 to about 10.00 grams of spent hops; from about 5 to about 1200 mg of 1,7-Bis(4- hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; from about 0.10 to about 24 mg of zinc; and from about 5 to about 1200 mg of 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a- dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
[0022] A method for promoting heavy metal detoxification in a mammal in need is described in another embodiment. Here the method comprises administering to the mammal a composition comprising a therapeutically effective amount of spent hops.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is a graphic representation of the chemical structure of 1,7-Bis(4- hydroxy-3-methoxyphenyl)hepta- 1 ,6-diene-3,5-dione.
[0024] Figure 2 is a graphic representation of the chemical structure of 3-(2-(Decahydro-
6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one.
[0025] Figure 3 depicts a Western blot analysis of Nrf-2 in the nuclear fraction of HepG2 cells treated for 4 hours with the indicated test compound. Formula DF-SH is the combination of spent hops, 7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione (curcumin), 3-(2- (Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one (andrographis), Rho dyhdro- isoalpha acids (RIAA) mixture and Zn (525:30:30:4:1).
[0026] Figure 4 depicts a Western blot analysis of Nrf-2 in the nuclear fraction of HepG2 cells treated for 4 hours with the indicated test compound. Formula 3 Components is the combination of Isoalpha acid (IAA), 7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5- dione (curcumin), and 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one (andrographis), (1 :1 :1).
[0027] Figure 5 graphically depicts the increased induction of metal lothionein mRNA levels in volunteers following administration of a test formulation comprising (per tablet): zinc (1.667 mg); 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one (50 mg); l,7-Bis(4-hydroxy- 3-methoxyphenyl)hepta-l,6-diene-3,5-dione (50 mg); spent hops (875 mg) and a Rho dihydro- isoalpha acid mixture (6.667 mg).
[0028] Figure 6 graphically depicts the increased induction of metallothionein mRNA levels measured using alternative primers in volunteers following administration of a test formulation comprising (per tablet): zinc (1.667 mg); 3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one (50 mg); l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione (50 mg); spent hops (875 mg) and a Rho dihydro-isoalpha acid mixture (6.667 mg).
[0029] Figure 7 graphically depicts the effects of test formulation on urinary excretion of clinically important metals. * denotes a detectable increase in excretion.
[0030] Figure 8 graphically depicts the effects of test formulation on urinary excretion of non-clinically important metals.
[0031] Figure 9 graphically depicts the effects of test formulation on urinary excretion of nutrients. * denotes a detectable increase in excretion.
DETAILED DESCRIPTION OF THE INVENTION
[0032] The present invention relates to compositions and methods to promote heavy metal detoxification under non-acute conditions in mammals. More specifically, the invention relates to the use of spent hops, zinc, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5- dione), and (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) or combinations thereof for heavy metal detoxification in the non-acute state.
[0033] The patents, published applications, and scientific literature referred to herein establish the knowledge of those with skill in the art and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference. Any conflict between any reference cited herein and the specific teachings of this specification shall be resolved in favor of the latter. Likewise, any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.
[0034] Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of recombinant DNA technology include Sambrook et ah, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989); Kaufman et ah, Eds., Handbook of Molecular and Cellular Methods in Biology in Medicine, CRC Press, Boca Raton (1995); McPherson, Ed., Directed Mutagenesis: A Practical Approach, IRL Press, Oxford (1991). Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th Ed., McGraw Hill Companies Inc., New York (2006).
[0035] In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. As used in this specification, the singular forms "a," "an" and "the" specifically also encompass the plural forms of the terms to which they refer, unless the content clearly dictates otherwise. Additionally, as used herein, unless specifically indicated otherwise, the word "or" is used in the "inclusive" sense of "and/or" and not the "exclusive" sense of "either/or." The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.
[0036] As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value of the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value of the numerical range, including the end-points of the range. As an example, a variable which is described as having values between 0 and 2, can be 0, 1 or 2 for variables which are inherently discrete, and can be 0.0, 0.1, 0.01, 0.001, or any other real value for variables which are inherently continuous.
[0037] Reference is made hereinafter in detail to specific embodiments of the invention.
While the invention will be described in conjunction with these specific embodiments, it will be understood that it is not intended to limit the invention to such specific embodiments. On the contrary, it is intended to cover alternatives, modifications, and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. The present invention may be practiced without some or all of these specific details. In other instances, well known process operations have not been described in detail, in order not to unnecessarily obscure the present invention.
[0038] Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention. However, preferred materials and methods are described. Materials, reagents and the like to which reference are made in the following description and examples are obtainable from commercial sources, unless otherwise noted.
[0039] A first embodiment of the invention describes compositions for promoting heavy metal detoxification in a mammal in need, where the compositions comprise a therapeutically effective amount of at least two members selected from the group consisting of spent hops; 1 ,7- Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; zinc; and 3-(2-(Decahydro-6- hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one.
[0040] In one aspect of this embodiment the compositions further comprise a compound selected from the group consisting of (41S',55)-3,4-dihydroxy-4-[(LS)-hydroxy-4-methylpent-3-en- l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4R,5R)-3,4- dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en- l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2- (2-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4- [( 1 i?)-hydroxy-4-methylpent-3-en- 1 -y l]-5-(3-methylbut-2-en- 1 -yl)-2-(2- methylpropanoyl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(15')-hydroxy-4-methylpent- S-en-l-ylJ^-CS-methylbutanoyO-S^-methylbut^-en-l-yOcyclopent^-en-l-one; (4i?,5i?)-3,4- dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en- l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(lS)-hydroxy-4-methylpent-3-en-l-yl]-5- (3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-4- [( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en- 1 - yl)cyclopent-2-en- 1 -one; (4i?,55)-3 ,4-dihydroxy-4-[( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(2- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-4-
[( li?)-hydroxy-4-methylpent-3-en- 1 -yl]-5-(3-methylbut-2-en- 1 -yl)-2-(2- methylpropanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-4-[(lS)-hydroxy-4-methylpent- 3-en- 1 -yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en- 1 -yl)cyclopent-2-en- 1 -one; (4i?,55)-3,4- dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en- l-yl)cyclopent-2-en-l-one; (4/?,55)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-5- (3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent-2-en-l-one; (45',5i?)-3,4-dihydroxy-4- [( 1 /?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en- 1 - yl)cyclopent-2-en- 1 -one; (45,5i?)-3 ,4-dihydroxy-4-[( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(2- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (45',5i?)-3,4-dihydroxy-4- [( 1 /?)-hydroxy-4-methylpent-3-en- 1 -yl]-5-(3-methylbut-2-en- 1 -yl)-2-(2- methylpropanoyl)cyclopent-2-en-l-one; (45',5i?)-3,4-dihydroxy-4-[(liS)-hydroxy-4-methylpent- 3-en- 1 -yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en- 1 -yl)cyclopent-2-en- 1 -one; (45,5i?)-3,4- dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylpropanoyl)-5-(3-methylbut-2- en-l-yl)cyclopent-2-en-l-one; (45,5i?)-3,4-dihydroxy-4-[(LS)-hydroxy-4-methylpent-3-en-l-yl]- 2-(2-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (45',55f)-3,4-dihydroxy-4- [(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l- yl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4-
[( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-5-(3-methylbut-2-en- 1 -yl)-2-(2- methylpropanoyl)cyclopent-2-en-l-one; (45f,5.S)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3- en- 1 -yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en- 1 -yl)cyclopent-2-en-l -one; and (45,5S)-S^- dihydroxy-4-[(LS)-hydroxy-4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2- methylpropanoyl)cyclopent-2-en- 1 -one.
[0041] In a further aspect of the embodiment, the compositions further comprise a compound selected from the group consisting of 4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5- (3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4R,5S)-3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4/?,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyI)cyclopent-2-en-l-one; (4i?,51S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3- methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,5»S)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,5»S)-3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3- methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4/?,5iS)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,5-S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (47?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3- methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cycIopent-2-en-l-one; and (4i?,55)- 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l- one. [0042] Compositions further comprising a compound selected from the group consisting of (4S',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methy lbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydro xy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(lS)-l- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cycIopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydro xy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,5S)-3,4-dihydroxy-4-[(lS)-l- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( IS)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S,5S)- 3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one; (45',55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydro xy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4-[(l S)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en- 1 -one; (45*,55)-3,4-dihydroxy-4-[( IS)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S,5S)- 3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45l,5.S)-3,4-dihydroxy-4-[(lS)-l- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S,5S)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one; (45',55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en- 1 -one; (4S,55)-3,4-dihydroxy-4-[( IS)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,5S)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydro xy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en- 1 -one; (45",55)-3,4-dihydroxy-4-[( IS)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S,5S)- 3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one; (45',55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; and (4iS1,5.S)-3,4-dihydroxy-4-[(l S)- 1 -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en- 1 -one are described in yet another aspect of this embodiment.
[0043] In some aspects of this embodiment the compositions further comprise a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents. In other aspects, the compositions further comprise one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.
[0044] As used herein, "promoting heavy metal detoxification" refers to inducing detoxification enzyme production, augmenting the enzymatic activity of existing detoxification enzymes, or inhibiting the inhibitors of the detoxification enzymes. Representative, non-limiting examples of detoxification enzymes include alcohol sulphotransferase, amine N- methyltransferase, amine O-sulphotransferase, arylamine N-acetyltransferase (NAT2), catechol O-methyltransferase, cysteine conjugate β-lyase, cysteine N-acetyltransferase, glycine acyltransferase, glutamate acyltransferase, glutathione S-transferases (GST), heme oxygenase- 1, histamine N-methyltransferase, microsomal epoxide hydrolase (mEH), metallothioneins, NAD(P)H: quinone oxidoreductase (NQOl), phenol O-methyltransferase, phenol sulphotransferase, rhodanese, thiol S-methyltransferase, thioltransferase, and UDP-glucuronosyl transferase (UDP-GT).
[0045] As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term "comprising" means that the compound or composition includes at least the recited features or components, but may also include additional features or components.
[0046] As used herein, "compounds" may be identified either by their chemical structure, chemical name, or common name. When the chemical structure and chemical or common name conflict, the chemical structure is determinative of the identity of the compound. The compounds described herein may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers or diastereomers. Accordingly, the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the illustrated or identified compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan. The compounds may also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated or identified compounds. The compounds described also encompass isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that may be incorporated into the compounds of the invention include, but are not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 17O, etc. Compounds may exist in unsolvated forms as well as solvated forms, including hydrated forms and as N-oxides. In general, compounds may be hydrated, solvated or N-oxides. Certain compounds may exist in multiple crystalline or amorphous forms. Also contemplated within the scope of the invention are congeners, analogs, hydrolysis products, metabolites and precursor or prodrugs of the compound. In general, unless otherwise indicated, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention.
[0047] Compounds according to the invention may be present as salts. In particular, pharmaceutically acceptable salts of the compounds are contemplated. A "pharmaceutically acceptable salt" of the invention is a combination of a compound of the invention and either an acid or a base that forms a salt (such as, for example, the magnesium salt, denoted herein as "Mg" or "Mag") with the compound and is tolerated by a subject under therapeutic conditions. In general, a pharmaceutically acceptable salt of a compound of the invention will have a therapeutic index (the ratio of the lowest toxic dose to the lowest therapeutically effective dose) of 1 or greater. The person skilled in the art will recognize that the lowest therapeutically effective dose will vary from subject to subject and from indication to indication, and will thus adjust accordingly.
[0048] The compositions according to the invention are optionally formulated in a pharmaceutically acceptable vehicle with any of the well known pharmaceutically acceptable carriers, including diluents and excipients (see Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, Mack Publishing Co., Easton, PA 1990 and Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins, 1995). While the type of pharmaceutically acceptable carrier/vehicle employed in generating the compositions of the invention will vary depending upon the mode of administration of the composition to a mammal, generally pharmaceutically acceptable carriers are physiologically inert and non-toxic. Formulations of compositions according to the invention may contain more than one type of compound of the invention), as well any other pharmacologically active ingredient useful for the treatment of the symptom/condition being treated. The term "pharmaceutically acceptable" is used in the sense of being compatible with the other ingredients of the compositions and not deleterious to the recipient thereof.
[0049] As used herein "hop" or "hops" refers to plant cones of the genus Humulus which contain a bitter aromatic oil which is used in the brewing industry to prevent bacterial action and add the characteristic bitter taste to beer. More preferably, the hops used are derived from Humulus lupulus.
[0050] The term "therapeutically effective amount" is used to denote treatments at amounts of the compositions effective to achieve the therapeutic result sought. Furthermore, one of skill will appreciate that the therapeutically effective amount may be lowered or increased by fine tuning and/or by administering more than one composition of the invention, or by administering a composition of the invention with another composition or compound. See, for example, Meiner, C. L., "Clinical Trials: Design, Conduct, and Analysis," Monographs in Epidemiology and Biostatistics, Vol. 8 Oxford University Press, USA (1986). The invention therefore provides a method to tailor the administration/treatment to the particular exigencies specific to a given mammal. As illustrated in the following examples, therapeutically effective amounts may be easily determined for example empirically by starting at relatively low amounts and by step-wise increments with concurrent evaluation of beneficial effect.
[0051] As used herein, the term "spent hops" refers to the solid and hydrophilic residue resulting from (1) exposing a hops plant product to a solvent, (2) separating the solvent from the hops plant products, and (3) eliminating the solvent. Representative solvents, without limitation, can include CO2, water, organic solvents (e.g., alcohols) or mixtures thereof.
[0052] l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione is presented graphically in Figure 1. As used herein, "l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene- 3,5-dione" refers to curcumin, a yellow pigmented fraction isolated from the rhizomes of Curcuma longa. The curcuminoids are considered the important active ingredients and are believed to be responsible for the biological activity of Curcuma longa. Though their major activity is anti-inflammatory, curcuminoids have been reported to possess antioxidant, antiallergic, wound healing, antispasmodic, antibacterial, antifungal and antitumor activity as well.
[0053] 3-(2-(Decahydro-6-hydroxy-5 -(hydroxymethy l)-5 , 8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one is presented graphically in Figure 2. As used herein, "3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one" refers to andrographolide / andrographis, a diterpene lactone. Diterpene lactone species, such as andrographolide are commonly found in plants and are used for their anti-inflammatory properties. Their mechanism of action is believed to be due (i) to the inhibition of histamine release from mast cells or (ii) to the inhibition of lipoxygenase and cyclooxygenase activity thereby reducing the synthesis of inflammatory factors produced during the arachidonic acid cascade.
[0054] As used herein, the term "reduced isoalpha acid" refers to alpha acids isolated from hops plant product and subsequently have been isomerized and reduced, including cis and trans forms. Examples of reduced isoalpha acids (RIAA) include without limitation dihydro- isoalpha acids, more specifically Rho dihydro-isoalpha acids (Table 1), tetra-hydroisoalpha acid (Table 2), and hexa-hydroisoalpha acids (Table 3), and their derivatives. "Rho" refers to those reduced isoalpha acids wherein the reduction is a reduction of the carbonyl group in the 4- methyl-3-pentenoyl side chain.
Table 1 Rho dihydro-isoalpha acids
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Table 2 Tetrahydro-isoalpha acids
Figure imgf000022_0002
Figure imgf000023_0001
Table 3 Hexahydro-isoalpha acids
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
[0055] As used herein, the terms "derivatives" or a matter "derived from" refer to a chemical substance related structurally to another substance and theoretically obtainable from it, i.e. a substance that can be made from another substance. Derivatives can include compounds obtained via a chemical reaction or de novo chemical syntheses. See Verzele, M. and De Keukeleire, D., Developments in Food Science 27: Chemistry and Analysis of Hop and Beer Bitter Acids, Elsevier Science Pub. Co., 1991, New York, USA, herein incorporated by reference in its entirety, for a detailed discussion of hops chemistry.
[0056] A second embodiment of the invention describes methods for promoting heavy metal detoxification in a mammal, where the methods utilize compositions which comprise a therapeutically effective amount of at least two members selected from the group consisting of spent hops; l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; zinc; and 3-(2- (Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
[0057] In one aspect of this embodiment the compositions of the method further comprise a compound selected from the group consisting of (4.S',55)-3,4-dihydroxy-4-[(15)- hydroxy-4-methylpent-3-en-l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2- en- 1 -one; (4i?,5i?)-3,4-dihydroxy-4-[( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4- [(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-l- yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-5-(3- methylbut-2-en- 1 -yl)-2-(2-methylpropanoyl)cyclopent-2-en- 1 -one; (4i?,5i?)-3,4-dihydroxy-4- [(LS)-hydroxy-4-methylpent-3-en-l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l- yl)cyclopent-2-en- 1 -one; (4i?,5i?)-3,4-dihydroxy-4-[( 15)-hydroxy-4-methy lpent-3-en- 1 -yl]-2-(2- methylbutanoyO-S-CS-methylbut^-en-l-yOcyclopent^-en-l-one; (4i?,5i?)-3,4-dihydroxy-4- [(lS)-hydroxy-4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2- methylpropanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent- 3-en- 1 -ylJ^-CS-methylbutanoyO-S-β-methylbut^-en- 1 -yl)cyclopent-2-en- 1 -one; (4R,5S)-3,A- dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en- l-yl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-5- (3-methylbut-2-en- 1 -yl)-2-(2-methylpropanoyl)cyclopent-2-en- 1 -one; (4R,5S)-3 ,4-dihydroxy-4- [( 15)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l - yl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4/?,55)-3,4-dihydroxy-4-
[( 15)-hydroxy-4-methy lpent-3-en- 1 -yl]-5-(3-methylbut-2-en- 1 -yl)-2-(2- methylpropanoyl)cyclopent-2-en-l-one; (45',5i?)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent- S-en-l-yll^^-methylbutanoyO-S^-methylbut^-en-l-yOcyclopent^-en-l-one; (45,5i?)-3,4- dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en- l-yl)cyclopent-2-en-l-one; (45',57?)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-5- (3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent-2-en-l-one; (45,5i?)-3,4-dihydroxy-4- [( 1 <S)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3-methy lbutanoyl)-5-(3-methylbut-2-en- 1 - yl)cyclopent-2-en- 1 -one; (45",5i?)-3,4-dihydroxy-4-[( 15)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(2- methylpropanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (45",5i?)-3,4-dihydroxy-4- [(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-l- yl)cyclopent-2-en-l-one; (41S,55)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4-
[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-l- yl)cyclopent-2-en-l-one; (45r,55)-3,4-dihydroxy-4-[(l/?)-hydroxy-4-methylpent-3-en-l-yl]-5-(3- methylbut-2-en- 1 -yl)-2-(2-methylpropanoyl)cyclopent-2-en- 1 -one; (4S,5S)-3 ,4-dihydroxy-4- [( 15)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en- 1 - yl)cyclopent-2-en-l-one; and (4lS',55)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-5- (3-methylbut-2-en- 1 -yl)-2-(2-methylpropanoyl)cyclopent-2-en- 1 -one.
[0058] In a further aspect of the embodiment, the compositions of the method further comprise a compound selected from the group consisting of 4i?,5.S)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4R,5S)-3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3- methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4/?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3- methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3 ,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4£,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3- methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4- dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; and (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en- 1 -one.
[0059] Compositions of the method further comprising a compound selected from the group consisting of (4S,55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(l S)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S,5S)- 3,4-dihydroxy-4-[( IS)-I -hydroxy^-methylpenty^^-CS-methylbutanoyO-S-CS- methylbutyl)cyclopent-2-en-l-one; (45',5ιS)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2- (S-rnethylbutanoyO-S-CS-methylbutyOcyclopent^-en-l-one; (45',5lS)-3,4-dihydroxy-4-[( IS)-I - hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en-l-one; (45,5,S)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2- (S-methylbutanoyO-S-CS-methylbutyOcyclopent^-en-l-one; (45f,55)-3,4-dihydroxy-4-[( IS)-I - hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(l S)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[( IS)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( 1 S)-I -hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(l S)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[( IS)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dlhydroxy-4-[( 1 S)- 1 -hydro xy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[(l S)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyI)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)- 3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydro xy-4-methylpentyl]-2- (3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4-[( IS)-I - hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; and (45,55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en-l-one are described in yet another aspect of this embodiment.
[0060] In some aspects of this embodiment the compositions used further comprise a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents. In other aspects the compositions of the methods further comprise one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates. [0061] The methods of the present invention are intended for use with any mammal that may experience the benefits of the methods of the invention. Foremost among such mammals are humans, although the invention is not intended to be so limited, and is applicable to veterinary uses. Thus, in accordance with the invention, "mammals" or "mammals in need" include humans as well as non-human mammals, particularly domesticated animals including, without limitation, cats, dogs, and horses.
[0062] A composition comprising: from about 0.10 to about 10.00 grams of spent hops; from about 5 to about 1200 mg of l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5- dione; from about 0.10 to about 24 mg of zinc; and from about 5 to about 1200 mg of 3-(2- (Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one is described in a third embodiment of the invention while a further embodiment of the invention describes methods for promoting heavy metal detoxification in a mammal, where the methods utilize compositions comprising from about 0.10 to about 10.00 grams of spent hops; from about 5 to about 1200 mg of l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione; from about 0.10 to about 24 mg of zinc; and from about 5 to about 1200 mg of 3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one.
[0063] A further embodiment of the invention describes methods for promoting heavy metal detoxification in a mammal utilizing a composition comprising a therapeutically effective amount of spent hops.
[0064] The following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. EXAMPLES
Example 1
Effects of test compounds on detoxification enzyme activity
[0065] Test Materials - All test compounds were supplied by Metagenics (San Clemente,
CA., USA). Test compounds were prepared in dimethyl sufoxide (DMSO) and stored at -200C. Sulforaphane, glutathione and 1-Chloro 2, 4-dinitro benzene (CDNB) were purchased from Sigma Chemicals (St.Louis, MO). All other general chemicals were analytical grade.
[0066] Cell culture and treatment -The rat liver cell line RL-34 was purchased from the
Japan Health Science Foundation (Tokyo, Japan). Cells were maintained in log phase in DMEM media supplemented with 5% heat inactivated FBS, 100 IU penicillin, and 100 μg/ml streptomycin. The human liver cell line HepG2 was purchased from ATCC (Manassas, VA). Cells were maintained in log phase in MEM media supplemented with 10% heat inactivated FBS, 100 IU penicillin, and 100 μg/ml streptomycin.
[0067] Enzymatic activity in RL-34 cells - Cells were subcultured in 6-well plates at a density of 3 x 105 cells per well. The following day test compounds in DMSO were added at a final 0.1% DMSO concentration. The cells were incubated with test compound for 2 days in a humidified incubator at 37°C after which the cells were lysed and assayed for enzyme activity. Following treatment with test compounds, cells were washed twice with 0.5 ml PBS and all residual liquid was removed. To lyse the cells, 150 μL Buffer D (0.8% digitonin in 2 mM EDTA) was added to each well and incubated for 15 minutes at room temperature. The cell lysate was centrifuged for 10 minutes at 10,000 rpm. The supernatant containing the cell lysate was transferred into a 96-well plate. Protein determination was performed using the Bicinchoninic Acid Kit (Sigma, St. Louis, MO). Equal protein concentrations were used in all enzyme activity assays.
[0068] GST activity assay - Cell lysate (20 μL) containing the GST enzyme was added to each well of a UV flat bottom 96 well microtiter plate. Reaction buffer was added (300 μL) to each well to achieve a final concentration of 8 mM glutathione and 3.2 mM CDNB in 100 mM KPO4. The enzymatic conversion of CDNB was measured at 340 nm over three minutes to determine a rate of GST activity (Apati, P., et al., J Pharm Pharmacol, 58(2): 251-6, 2006, and Habig, W.H., MJ. Pabst, and W.B. Jakoby, J Biol Chem., 249: 7130-9, 1974).
[0069] NADPH quinone oxido reductase assay (NQOl) - To assay NQOl activity, 20 μL of cell lysate containing the NQOl enzyme was added to each well of a flat bottom 96 well microtiter plate. Reaction buffer was added (200 μL) to each well to achieve a final concentration of 25 mM Tris-HCl, pH 7.4, 5 μM FAD, 1 mM G6P, 30 μM NADP, 2 U/ml G6PDH, 0.06% BSA, 725 μM MTT and 50 μM menadione. The reduction of MTT at 610 nm was measured after three minutes to determine the induction of NQOl activity (Feng, R., et al., J Biol Chem, 280(30): 27888-95, 2005. and Prochaska, HJ. and A.B. Santamaria, Anal Biochem., 169: 328-36, 1988). The induction of NQOl activity was determined as the ratio of treated over vehicle control.
[0070] Co-transfection of Reporter and Expression Plasmids - Construction of the heme oxygenase reporter was described previously (Gong, P., et al., Arch Biochem Biophys, 405(2): 265-74, 2002). The Lipofectamine 2000 transfection reagent from Invitrogen was used to perform the transfections by procedures as described in the manufacturer's protocol. HepG2 cells were subcultured in 96-well white plates at a density of 5 x 104 cells per well in MEM medium without serum and antibiotics. The following day dilute HO-I reporter construct with pRL-TK (0.2 μg total DNA in a ratio of 2:1) in 25 μL of opti-MEM and mix gently. Dilute 0.5 μL of Lipofectamine 2000 in 25 μL of opti-MEM and incubate for 5 minutes at room temperature. Then combine the diluted DNA with diluted Lipofectamine 2000, mix gently and incubate for 20 min at room temperature. The cells were incubated with 50 μl of above complex for 6 hours in a humidified incubator at 370C. After 6 hours of incubation, 100 μL MEM medium without serum and antibiotics were added and incubated for 18 hours. The medium was discarded and test compounds in DMSO were added at a final 0.1% DMSO concentration for 24 hours. The plasmid pRL-TK encoding Renilla luciferase was used as the internal control of each transfection.
[0071] Luciferase activity — Two days after the transfection, cells were washed with phosphate-buffered saline and lysed in passive lysis buffer from the Dual Luciferase reporter assay system per the manufacturer's protocol (Promega). First, the cell lysate was assayed for the firefly luciferase activity using 100 μl of the substrate LARII. Then 100 μl of the STOP & GLO reagent was added to quench the firefly luciferase activity and activate the Renilla luciferase, which was also measured. The assays were carried out in a PerkinElmer luminometer, and the relative luciferase activity was calculated as follows: 100,000/activity of Renilla luciferase (in units) 3 activity of firefly luciferase (in units). Each set of transfections was repeated three times.
[0072] Quantitative PCR - HepG2 cells were subcultured in 6-well plates at a density of
3 x 105 cells per well. The following day test compounds in DMSO were added at a final 0.1% DMSO concentration. The cells were incubated with test compound for 8 hours in a humidified incubator at 37°C. The mRNA was then purified for gene expression analysis using TRI reagent (Sigma Chemicals) according to the manufacture's instructions. Following mRNA purification, the cDNA template was generated for use in the QPCR analysis. This was performed with the Omniscript RT kit (Qiagen, Valencia, CA) at 370C for 60 min in a Techgene thermocycler (Techne, Burlington, NJ) to yield a 20 μL reaction with 2 μg starting mRNA. The blinded samples were sent to Dr. John Tine at the Center for Functional Genomics, University at Albany (Renesselaer, NY). Quantitative PCR was performed utilizing Taqman® chemistry and ΔΔCt quantification. Assays were performed in triplicate with 20 ng total RNA per well and GADPH as the internal control. The remaining five genes analyzed were GSTAl, NQOl, HMOXl, and two groupings of metallothioneins, hMTl&2 and hMTl&2alt. The protocol for metallothionein gene expression was taken from the work by Aydemir et al (Proc Natl Acad Sci U S A, 103(6): 1699-704, 2006), where a combination of two forward primers, two reverse primers, and two Taqman® probes gave matches for MTlH, -1H-Iike, -IG, -IL, -IE, -IA, and MT2.
[0073] Western blot detection - The HepG2 cell line was cultured as above and test compounds were added for four hours, after which the cells were lysed and the nuclear fraction was isolated (Dignam, J. D., R.M. Lebovitz, and R.G. Roeder, Nucleic Acids Res, 11(5): 1475- 89, 1983). Total protein concentration was determined using the Bicinchoninic Acid Kit (Sigma). Total cell lysates (60 μg total protein) were electrophoresed and detection of Nrf-2 was performed using primary antibody incubation overnight at 4°C (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). Secondary antibody linked to horseradish peroxidase was incubated for one h (GE Healthcare, Piscataway, NJ), after which proteins were visualized using the enhanced chemiluminescence (ECL) system. Densitometry was performed using Kodak Molecular Imaging Software v.4.0 (Eastman Kodak Company, Rochester, NY) measuring the net intensity of the band.
[0074] Statistical analysis - The induction of GST and NADPH quinone reductase assay activity were determined as the ratio of treated with test compounds over vehicle (DMSO) control. GST and NQOl activity was normalized for equal protein. A minimum of two wells were used for each condition. The induction of heme oxygenase promoter activity was determined as the ratio of treated with test compounds over vehicle control. Luciferase activity was normalized with Renilla luciferase activity as a control. A minimum of 4 wells were used for each condition. The data represents the average of three independent experiments (SEM).
RESULTS
[0075] Enzymatic activity - Sulforaphane is a known activator of Nrf-2 and was used as a control in the enzymatic activity assays. According to the convention of the scientific literature, 20% induction of activity by test compounds over DMSO control is considered active. GST activity (Table 4) was induced > 20% by Sulforaphane (3 μg/ml), Andrographis (25 μg/ml), Xanthohumol (1 μg/ml), Prune (20 μg/ml), Withania (20 μg/ml), Osteosine (20 μg/ml), MCHA (20 μg/ml), and Arthred Porcine (20 μg/ml) in RL-34 cell line. NQOl enzymatic activity (Table 5) was induced > 20% by (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin) (5 μg/ml), (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) (andrographis) (25 μg/ml), Xanthohumol (1 μg/ml), Sulforaphane (3 μg/ml), Withania (20 μg/ml), I3C (25 μg/ml), Resveratrol (20 μg/ml), Milk Thistle (25 μg/ml), IAA (5 μg/ml), Pomegranite (25 μg/ml), Parthenolide (20 μg/ml), AmIa (25 μg/ml) , Oleanolic acid (25 μg/ml), DIM (25 μg/ml), Quercetin (20 μg/ml), Berberine (20 μg/ml), Cinnamon (25 μg/ml), Puerariae (20 μg/ml), Wasabia Rhizome (25 μg/ml), Watercress (25 μg/ml), Epimedium (20 μg/ml), chlorogenic acid (25 μg/ml), Abelmoschus (20 μg/ml), Bonistein (20 μg/ml), Peppermint (25 μg/ml), Blueberry (25 μg/ml), Picrorhiza (25 μg/ml), Wasabia Powder (25 μg/ml), HHIAA (5 μg/ml), Osteosine (20 μg/ml), Dandelion (25 μg/ml), Green Coffee (25 μg/ml) and THIAA (5 μg/ml). Table 4 Screening of test compounds for GST enzyme activity in the RL-34 cell line
Figure imgf000036_0001
[0076] Formula DF-SH is the combination of spent hops, (l,7-Bis(4-hydroxy-3- methoxyphenyl)hepta- 1 ,6-diene-3,5-dione) (curcumin), (3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one) (andrographis), Rho Isoalpha acid and Zn (525:30:30:4:1) Table 5 Screening of test compounds for NQO-I enzyme activity in the RL-34 cell line
Figure imgf000037_0001
[0077] Formula DF-SH is the combination of spent hops, (l,7-Bis(4-hydroxy-3- methoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin), (3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one) (andrographis), Rho Isoalpha acid and Zn (525:30:30:4:1) [0078] HO-I Transcriptional activation - Heme oxygenase is regulated by both Nrf-2 and MTF-I transcriptional factors through the activation of ARE and MRE binding sites on heme oxygenase gene. Sulforaphane, a known compound for the activation of Nrf-2 transcriptional factor induces the heme oxygenase promoter activity in the HepG2 cell line (Table 6). Thirty percent induction of the activity by test compounds over DMSO control is considered as active. Test compounds (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene- 3,5-dione) (curcumin), xanthohumol, (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a- dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) (andrographis) extract, sulforaphane, IAA, oleanolic acid, green tea catechins, milk thistle, terminalin, ZnCl2, garlic, amla fruit extract and cinnamon ground induced the expression of heme oxygenase promoter activity.
Table 6
Activation of the heme oxygenase (HO-I) luciferase reporter by test compounds in the HepG2 cell line
Figure imgf000038_0001
[0079] Gene Expression - The relative expression (RE) of the genes analyzed was reported relative to GAPDH. To determine the relative expression to the control cells, the ratio of treatment to the DMSO control average RE value was calculated for all samples. The average of hMTl&2 and hMTl&2alt was calculated and expressed as MT 1,2. The average of GSTAl and NQOl was calculated and expressed as Phase II gene induction. The average gene expression for metallothionein (MT 1,2), heme oxygenase (HMOXl), and phase II enzymes (GSTAl and NQOl) is seen in Table 7. As a control, CdCl2, was shown to induce both MT and HMOXl, however was unable to increase phase II. Alternatively, sulforaphane increased phase II and HMOXl, but not MT. Test compounds that increased > 20% (in rank order) phase II include andrographis, IAA and curcumin; HMOXl include curcumin, andrographis, fucus mesh, gymnogongrus, IAA, and xanthohumol; MT include oleanolic acid, fucus mesh, xanthohumol and gymnogongrus.
Table 7
Gene expression in HepG2 cells following treatment with test compounds (values shown are μg/ml)
MT 1 ,2 (ave) HMOX1 Phase Il (ave)
Ratio to DMSO +/- SD Ratio to DMSO +/- SD Ratio to DMSO +/- SD
DMSO Control 1.00 0.26 1.00 0.15 1.00 0.09
CdCI2 (40 uM) 83.31 18.50 21.23 5.28 0.94 0.23
Sulforaphane (3) 0.67 0.16 8.82 1.98 1.84 0.44
Andrographis (25) 0.87 0.12 2,43 0.37 2.29 0.39
Curcumin (5) 0.90 0.48 2.09 1.14 1.15 043
ZnCI2 (10) 12.43 8.98 0.97 0.16 0.94 0.09
IAA (5) 0.89 0.12 1.26 0.15 1.26 0.18
RIAA (5) 0.83 0.22 2.54 1.82 1.15 0.35
THIAA (5) 0.90 0.17 1.11 0.01 0.99 0.13
Xanthohumol (1) 0 90 0.40 1.11 0.12 1.02 0.19
Spent Hops (20) 1.35 0.31 1.31 0.15 0.69 0.29
Spent Hops (50) 2.12 0,61 1.25 0.08 1.14 0.64
SH formula (10) 0.95 0.13 1.64 0.20 1.06 0.07
SH formula (20) 1.04 0.13 3 55 0.15 1.52 0.07
SH formula (50) 0.79 0.30 1.14 0.12 0.66 0.09
3C formula (1 ) 1.15 0.14 0.85 0.12 0.84 0.16
3C formula (2.5) 1.05 0.11 1.03 0.05 1.00 0.20
3C formula (5) 2.07 2.00 30.34 49.01 29,93 59.01
3C formula (7.5) 1.12 0.11 2.14 0.33 11.12 21.07
Oleanolic (25) 2.39 0.52 1.88 1.41 0.91 0.27
Withania (20) 1 06 0.18 1 17 0.23 0 98 0.24
As. Nod Mesh (25) 1.05 0.08 0.82 0.02 0.68 0.16
C. Chamissoi (25) 1.01 0.07 1.04 0.13 0.86 0.15
C. Crispus (25) 1.07 0.18 0.90 0.20 0.79 0.16
Fucus Mesh (25) 1.28 0.18 2.12 1.37 6.82 11.77
Green Tea (25) 0.85 0.09 0.77 0.00 0.83 0.11
Gymnogongrus (25) 1.19 0.03 1.63 0.89 0.97 0.02
Irish Moss (25) 2.07 2.26 0.91 0.07 0.91 0.07
Sarcodiotheca (25) 0.88 0.09 0.85 0.15 0.77 0.08
[0080] 3C formula is the combination of equal ratios of IAA, (l,7-Bis(4-hydroxy-3- rnethoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin), and (3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran- 2(3H)-one) (andrographis). SH formula is the combination of spent hops, Rho Isoalpha acid, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin), (3-(2-(Decahydro- 6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one) (andrographis), and zinc (525:4:30:30:1). The gray shading indicates only one replicate
[0081] Nrf-2 Translocation - The translocation of Nrf-2 from the cytoplasm to the nucleus has been shown to occur with treatment of xenobiotics and antioxidants (Chan, J. Y. and M. Kwong, Biochim Biophys Acta, 1517(1): 19-26, 2000, and Chan, K., et al., Proc Natl Acad Sci U S A, 93(24): 13943-8, 1996). As seen in Figures 3 and 4, Nrf-2 was observed in the nuclear fraction of HepG2 cells treated with test compound after 4 hours. As a control, sulforaphane displayed a dramatic increase in Nrf-2 nuclear translocation. The combination of spent hops, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene-3,5-dione) (curcumin), (3-(2- (Decahydro-6-hydroxy-5-(hydroxyrnethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) (andrographis), Rho Isoalpha acid and Zn (525:30:30:4:1) and IAA, (l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene- 3,5-dione) (curcumin), (3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one) (andrographis) (1 :1 :1) also showed a marked translocation of Nrf-2 to the nucleus.
Example 2
Effects of test formulation on metallothionein inRNA production
[0082] This experiment was a study investigating the effects of a unique nutraceutical combination upon biomarkers of metal detoxification and elimination.
[0083] Nine volunteers were recruited and followed for 14 days. Baseline evaluations were obtained at Visit 1. Treatment with a test formulation comprising (per tablet): zinc (1.667 mg); 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2- methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one (50 mg); l,7-Bis(4-hydroxy- 3-methoxyphenyl)hepta-l,6-diene-3,5-dione (50 mg); spent hops (875 mg) and a Rho dihydro- isoalpha acid mixture (6.667 mg) was begun immediately thereafter and continued for 10 days.
[0084] Clinical evaluations were made at Visit 2 (Day 3), Visit 3 (Day 6), Visit 4 (Day
8), Visit 5 (Day 10), and Visit 6 (Day 14). Visit 6 occurred 4 days after discontinuation of treatment. Basic safety labs at visits 1 and 5 were obtained including complete blood counts, comprehensive metabolic panels and gamma glutamyl transferase levels. Efficacy endpoints included messenger RNA levels of Metallothionein 1 and 2 (reflecting gene up-regulation) and unprovoked urinary excretion of toxic and nutrient trace elements. [0085] Metal lothionein mRNA measurements estimations in human blood samples were performed as follows:
[0086] RNA Extraction - After collection, 2ml whole blood was mixed with 5 ml of
RNAlater (Ambion, Austin, TX). RNA extractions were performed with the RiboPure Blood RNA Isolation Kit (Ambion, Austin, TX) according to the manufacturers specifications. RNA was quantified with a Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, DE).
[0087] Reverse Transcriptase Assays - RNA was converted to first strand cDNA by use of the RETROscript First Strand Synthesis Kit (Ambion, Austin, TX) and primed with oligo-dT according to the manufacturers specifications.
[0088] Primers and Probes - A Taqman gene expression assay to quantify GAPDH expression, which was used as an endogenous control, was obtained from Applied Biosystems (Foster City, CA; assay Hs99999905_ml). Primers and probes for Taqman-based assays targeting human metallothioneins have been previously described (Aydemir TB, Blanchard RK, and Cousins RJ, 2006. Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. Proc. Natl. Acad. Sci. USA 103, 1699-1704). Forward and reverse primers, and HPLC -purified Taqman probes labeled with 5'-FAM and 3'-TAMRA, were obtained from Operon Biotechnologies, Inc (Huntsville, AL).
[0089] The sequences of these reagents are shown below.
hMTl,2-F 5'- GCACCTCCTGCAAGAAAAGCT hMTl,2-R 5'- GCAGCCTTGGGCACACTT hMT 1 ,2-T 5 ' - FAM C AC AGCCC AC AGGGC AGC AGG TAMRA hMTl, 2AIt-F 5'- GCACCTCCTGCAAGAAGAGCT hMTl, 2AIt-R 5'- GCAGCCCTGGGCACACTT hMTl, 2AIt-T 5'- FAM ACAGCCCACAGGACAGCAGG
[0090] Quantitative PCR Assays - Two-step Taqman-based RT-qPCR was performed.
First strand cDNA was synthesized as described above. In the first experiment, the cDNA equivalent of 20 ng starting RNA was then included in qPCR reactions. Reactions to detect metallothionein expression contained IX Taqman Master Mix (Applied Biosystems, Foster City, CA), forward and reverse primers at 400 nM, and Taqman probe at 200 nM. Reactions to detect GAPDH expression contained IX Taqman Master Mix (Applied Biosystems) and IX gene- specific assay reagents as recommended by the manufacturer (Applied Biosystems). All reactions were run in triplicate. Reactions that did not contain template cDNA were included as negative controls. In a second experiment with a subset of the samples, the cDNA equivalent of 100 ng starting RNA was included in qPCRs with the other conditions as described above. A reference sample was included in both assays to allow cross-assay comparison.
[0091] Reaction plates were processed on an Applied Biosystems 7900HT Sequence
Detection System. The AmpliTaq Gold polymerase was activated at 950C for 10 min followed by 40 cycles consisting of denaturation for 15 seconds at 950C and annealing and extension for 60 seconds at 6O0C.
[0092] Amplification data was analyzed with the ABI Prism SDS 2.1 software (Applied
Biosystems). Relative quantification of gene expression was performed by the ΔΔCt method (Winer J, Jung CKS, Shackel I, Williams, PM. 1999. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 270, 41-49), with GAPDH expression serving as an endogenous control to normalize expression within each sample.
[0093] Results are depicted graphically in Figures 5 and 6 demonstrating the efficacy of the intervention in increasing measures of hepatic detoxification metallothionein mRNA levels.
Example 3
Effects of test formulation on urinary excretion of heavy metals
[0094] This study was conducted to determine the effects of a test formulation on urinary excretion of heavy metals in human volunteers.
[0095] Study Design - The study group and treatment regimen were as described in
Example 2 above. Urine samples were collected and heavy metal determination performed by Genova Diagnostics, North Carolina, USA according to their in house procedures. [0096] Results - Table 8 reports on the elimination of clinically relevant trace elements in test volunteers. Figures 7 and 8 graphically display the results of a test formulation on the excretion of clinically important (Figure 7) and non- clinically important metals (Figure 8). As can be seen in Figure 7, the test formulation significantly promoted excretion of a number of important metals. Figure 9 graphically displays the results of the test formulation on nutrient excretion in the urine.
Table 8 Urinary Excretion of Heavy Metals
Figure imgf000044_0001
* = amounts reported are in μg/g creatinine unless otherwise noted. = reported as mg/dL
= data presented only for subjects with detectable levels of metal
ND = below detectable limits.

Claims

1. A composition for promoting heavy metal detoxification in a mammal in need thereof, said composition comprising a therapeutically effective amount of at least two members selected from the group consisting of spent hops; l,7-Bis(4-hydroxy-3- methoxyphenyl)hepta-l,6-diene-3,5-dione; zinc; and 3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hy droxy furan-2(3 H)-one .
2. The composition according to Claim 1 , wherein the composition further comprises a compound selected from the group consisting of (4S,5S)-3,4-dihydroxy-4-[(l,S')- hydroxy-4-methy lpent-3 -en- 1 -y l]-2-(3 -methy lbutanoy I)-5 -(3 -methy lbut-2-en- 1 - yl)cyclopent-2-en- 1 -one; (4/?,5i?)-3,4-dihydroxy-4-[( 1 i?)-hydroxy-4-methy lpent-3 -en- l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (47?,5i?)- 3,4-dihydroxy-4-[(17?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(li?)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- 2-en-l-one; (4i?,5/?)-3,4-dihydroxy-4-[(l>S)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methy lbutanoy l)-5 -(3 -methy lbut-2-en- 1 -y l)cyclopent-2-en- 1 -one; (4R,5R)-3 ,4- dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(LS)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- 2-en- 1 -one; (4i?,55)-3,4-dihydroxy-4-[( li?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3- methy lbutanoy l)-5 -(3 -methy lbut-2-en- l-yl)cyclopent-2-en-l -one; (4R,5S)-3,4- dihydroxy-4-[(l/?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,55')-3,4-dihydroxy-4-[(li?)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- 2-en-l-one; (47?,55)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4R,5S)-3,4- dihydroxy-4-[( 15)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-4-[(15)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- 2-en-l-one; (45',5i?)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4S,5R)-3,4- dihydroxy-4-[( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en- 1 -yl)cyclopent-2-en- 1 -one; (45,5i?)-3,4-dihydroxy-4-[( 1 i?)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- 2-en-l-one; (45,5i?)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5-(3-methylbut-2-en-l-yI)cyclopent-2-en-l-one; (4S,5R)-3,4- dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylpropanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4S,5R)-3 ,4-dihydroxy-4-[( 15)-hydroxy- 4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2- en-l-one; (4,S',5lS)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5-(3-methyIbut-2-en-l-yl)cyclopent-2-en-l-one; (4S,5S)-3,4- dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4S,5LS)-3 ,4-dihydroxy-4-[( li?)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- 2-en- 1 -one; (45>,55')-3,4-dihydroxy-4-[( 15)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(2- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; and (4S,5S)-3,4- dihydroxy-4-[( 15)-hydroxy-4-methylpent-3-en- 1 -yl]-5-(3-methylbut-2-en- 1 -y l)-2-(2- methylpropanoyl)cyclopent-2-en- 1 -one.
3. The composition according to Claim 1, wherein the composition further comprises a compound selected from the group consisting of 4i?,5S)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,5<S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methyIbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one;
(4Λ,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,5S)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one;
(4i?,5S>3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,55)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one;
(4i?,5S>3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; (4i?,5S)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one;
(4i?,55)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one; and (47?,5iS)-3,4-dihydroxy-2-(3- methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one.
4. The composition according to Claim 1 , wherein the composition further comprises a compound selected from the group consisting of (4S,5S)-3 ,4-dihydroxy-4-[( IS)-I - hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l- one; (45,55)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (4S,5S)-3 ,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4iS,5.S)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (45",55)-3 ,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (4S,5S)-3 ,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en- 1 -one; (45,55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (4S,5S)-3 ,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (4lS',51Sr)-3,4-dihydroxy-4-[(l S)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoy^-S-CS-methylbutyOcyclopent-l-en-l-one; (4S,5S)-3 , 4-dihydroxy-4- [( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45f,5S)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45>,51S)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S,5S)-3 , 4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (4S',55l)-3,4-dihydroxy-4-[(l S)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (4S,5S)-3 ,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',5iS)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',55)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45l,55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l -one; (4S,5S)-3 ,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (4.S>,55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; and (45",5iS)-3,4-dihydroxy- 4-[( IS)-I -hydroxy^-methylpentyπ^-CS-methylbutanoylVS-CS- methylbutyl)cyclopent-2-en- 1 -one.
5. The composition according to Claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.
6. The composition according to Claim 1, wherein the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.
7. A method for promoting heavy metal detoxification in a mammal in need thereof, said method comprising administering to the mammal in need a composition comprising a therapeutically effective amount of at least two members selected from the group consisting of spent hops; l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6- diene-3,5-dione; zinc; and 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a- dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one.
8. The method according to Claim 7, wherein the composition used further comprises a compound selected from the group consisting of (4Sl,5»S)-3,4-dihydroxy-4-[(l,S)- hydroxy-4-methylpent-3-en-l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l- yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(17?)-hydroxy-4-methylpent-3-en- l-yl]-2-(3-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,5i?)- 3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en- 1 -yl)cyclopent-2-en- 1 -one; (4i?,5i?)-3,4-dihydroxy-4-[( li?)-hydroxy- 4-methylpent-3-en- 1 -yl]-5-(3-methylbut-2-en- 1 -y l)-2-(2-methylpropanoyl)cyclopent- 2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5 -(3 -methy lbut-2-en- 1 -y l)cyclopent-2-en- 1 -one; (4R,5R)-3 ,4- dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,5i?)-3,4-dihydroxy-4-[(lδ)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- 2-en- 1 -one; (4i?,55)-3,4-dihydroxy-4-[( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3- methylbutanoyl)-5-(3-methyIbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,55<)-3,4- dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- rnethy lbut-2-en- 1 -yl)cyclopent-2-en- 1 -one; (4i?,55)-3,4-dihydroxy-4-[( 1 i?)-hydroxy- 4-methylpent-3-en- 1 -yl]-5-(3-methylbut-2-en- 1 -yl)-2-(2-methylpropanoyl)cyclopent- 2-en-l-one; (4i?,55)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4R,5S)-3,4- dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4i?,5.S)-3,4-dihydroxy-4-[(15)-hydroxy- 4-methylpent-3-en- 1 -yl]-5-(3-methylbut-2-en- 1 -yl)-2-(2-methylpropanoyl)cyclopent- 2-en- 1 -one; (4S,5i?)-3,4-dihydroxy-4-[( 1 i?)-hydroxy-4-methylpent-3-en- 1 -yl]-2-(3- methy lbutanoyl)-5 -(3 -methy lbut-2-en- 1 -yl)cyclopent-2-en- 1 -one; (45, 5R)-3 ,4- dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (45',5i?)-3,4-dihydroxy-4-[(l/?)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- 2-en-l-one; (45',57?)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5-(3-methyIbut-2-en-l-yl)cyclopent-2-en-l-one; (4S,5R)-3,4- dihydroxy-4-[(liS)-hydroxy-4-methylpent-3-en-l-yl]-2-(2-methyIpropanoyl)-5-(3- methylbut-2-en- 1 -yl)cyclopent-2-en- 1 -one; (45r,5i?)-3,4-dihydroxy-4-[( 15)-hydroxy- 4-methylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2- en-l-one; (41S,5,S)-3,4-dihydroxy-4-[(li?)-hydroxy-4-methylpent-3-en-l-yl]-2-(3- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; (4S,5S)-3 ,4- dihydroxy-4-[(17?)-hydroxy-4-rnethylpent-3-en-l-yl]-2-(2-methylbutanoyl)-5-(3- methylbut-2-en-l-yl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4-[(li?)-hydroxy- 4-methylpent-3-en-l-yl]-5-(3-methylbut-2-en-l-yl)-2-(2 -methy lpropanoyl)cyclopent- 2-en-l-one; (41S',55)-3,4-dihydroxy-4-[(15)-hydroxy-4-methylpent-3-en-l-yl]-2-(2- methylbutanoyl)-5-(3-methylbut-2-en-l-yl)cyclopent-2-en-l-one; and (45l,55)-3,4- dihydroxy^-fCl^-hydroxy^-methylpent-S-en-l-yll-S-CS-methylbut^-en-l-yl)^^- methy lpropanoyl)cyclopent-2-en- 1 -one.
9. The method according to Claim 7, wherein the composition used further comprises a compound selected from the group consisting of (4iS',55)-3,4-dihydroxy-4-[(l S)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l- one; (45',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,55)-3,4-dihydroxy-4- [( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45,55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45f,55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyI)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45,5S)-3,4-dihydroxy-4-[(l S)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4tS',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45,55")-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',51S)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45r,55')-3,4-dihydroxy-4-[(l S)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4!S^S)-S ,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l -one; (45",55)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4lSI,5»S)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l -one; (45",55)-3,4-dihydroxy-4-[( I S)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (45',55)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (45,55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55I)-3 ,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (45I ;5.S)-3,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55<)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (45,55)-3 ,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45,5iS)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (45',55)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; and (45',55)-3,4-dihydroxy- 4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one.
10. The method according to Claim 7, wherein the composition used further comprises a compound selected from the group consisting of (4S,5S)-3, 4-dihydroxy-4-[(l S)-I- hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l- one; (45',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (41Sr,55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',55)-3,4-dihydroxy-4-[( IS)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (4IS',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4S,5S)-3 ,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',55)-3,4-dihydroxy-4-[(l S)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [( I S)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',5,S)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45*,5tS)-3,4-dihydroxy-4- [( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (4S,5S)-3 ,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpenty l]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45r,51S)-3,4-dihydroxy-4- [( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',5lS)-3,4-dihydroxy-4-[(l S)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45f,5.S)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (45',55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45l,55<)-3,4-dihydroxy-4- [( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (4S',51S)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (4»S,55)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en- 1 -one; (45',55)-3,4-dihydroxy-4-[( 1 S)- 1 -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',55)-3,4-dihydroxy-4- [( IS)-I -hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45',55)-3,4-dihydroxy-4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; (45',5iS)-3,4-dihydroxy-4- [(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3-methylbutyl)cyclopent- 2-en-l-one; (45,55)-3,4-dihydroxy-4-[(l S)-I -hydroxy-4-methylpentyl]-2-(3- methylbutanoyl)-5-(3-methylbutyl)cyclopent-2-en-l-one; and (45',5iS)-3,4-dihydroxy- 4-[(lS)-l-hydroxy-4-methylpentyl]-2-(3-methylbutanoyl)-5-(3- methylbutyl)cyclopent-2-en- 1 -one.
11. The method according to Claim 7, wherein the composition used further comprises a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.
12. The method according to Claim 7, wherein the composition used further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.
13. A composition according to Claim 1, wherein the composition comprises:
a. from about 0.10 to about 10.00 grams of spent hops;
b. from about 5 to about 1200 mg of l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6- diene-3,5-dione;
c. from about 0.10 to about 24 mg of zinc; and d. from about 5 to about 1200 mg of 3-(2-(Decahydro-6-hydroxy-5-
(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one.
14. The method according to Claim 7, wherein the composition used comprises:
a. from about 0.10 to about 10.00 grams of spent hops;
b. from about 5 to about 1200 mg of l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6- diene-3,5-dione;
c. from about 0.10 to about 24 mg of zinc; and
d. from about 5 to about 1200 mg of 3-(2-(Decahydro-6-hydroxy-5- (hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4- hydroxyfuran-2(3H)-one.
15. A method for promoting heavy metal detoxification in a mammal in need thereof, said method comprising administering to the mammal in need a composition comprising a therapeutically effective amount of spent hops.
PCT/US2008/053803 2007-05-11 2008-02-13 Methods and compositions for heavy metal detoxification WO2008140842A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN200880023922A CN101687834A (en) 2007-05-11 2008-02-13 The composition of heavy metal detoxification and method
EP08729724A EP2152684A4 (en) 2007-05-11 2008-02-13 Methods and compositions for heavy metal detoxification
JP2010508463A JP2010526882A (en) 2007-05-11 2008-02-13 Methods and compositions for detoxifying heavy metals
CA002686043A CA2686043A1 (en) 2007-05-11 2008-02-13 Methods and compositions for heavy metal detoxification
MX2009012087A MX2009012087A (en) 2007-05-11 2008-02-13 Methods and compositions for heavy metal detoxification.
AU2008251756A AU2008251756B2 (en) 2007-05-11 2008-02-13 Methods and compositions for heavy metal detoxification
NZ581064A NZ581064A (en) 2007-05-11 2008-02-13 Methods and compositions for heavy metal detoxification

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91742507P 2007-05-11 2007-05-11
US60/917,425 2007-05-11

Publications (1)

Publication Number Publication Date
WO2008140842A1 true WO2008140842A1 (en) 2008-11-20

Family

ID=40002565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/053803 WO2008140842A1 (en) 2007-05-11 2008-02-13 Methods and compositions for heavy metal detoxification

Country Status (10)

Country Link
US (2) US8241674B2 (en)
EP (1) EP2152684A4 (en)
JP (1) JP2010526882A (en)
KR (1) KR20100029201A (en)
CN (1) CN101687834A (en)
AU (1) AU2008251756B2 (en)
CA (1) CA2686043A1 (en)
MX (1) MX2009012087A (en)
NZ (1) NZ581064A (en)
WO (1) WO2008140842A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307465A (en) * 2008-12-10 2012-01-04 麦特普罗泰欧米克斯有限公司 A method for the purification of substituted cyclopent-2-en-1-one congeners and substituted 1,3-cyclopentadione congeners from a complex mixture using countercurrent separation
WO2012058649A1 (en) * 2010-10-30 2012-05-03 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
US9828331B2 (en) 2012-07-09 2017-11-28 Kindex Pharmaceuticals, Inc. Tetrahydro-isohumulone derivatives, methods of making and using

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9352274B2 (en) 2014-01-02 2016-05-31 Alstom Technology Ltd Apparatus and method for evaporating waste water and reducing acid gas emissions
US9724638B2 (en) 2014-01-02 2017-08-08 General Electric Technology Gmbh Apparatus and method for evaporating waste water and reducing acid gas emissions
US9650269B2 (en) 2014-11-25 2017-05-16 General Electric Technology Gmbh System and method for reducing gas emissions from wet flue gas desulfurization waste water
CN105259340B (en) * 2015-11-06 2017-01-11 宁波大学 Screening method of resisting joint toxicity of heavy metals by trisodium citrate dihydrate
US10350542B2 (en) 2016-04-29 2019-07-16 General Electric Company Wet flue gas desulfurization system with zero waste water liquid discharge

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037180A2 (en) * 2002-10-21 2004-05-06 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1901277U (en) 1964-05-25 1964-09-24 Kuhlmann Geb DEVICE FOR MAKING PERFORMANCE IN PROFILE BARS.
US3933919A (en) * 1964-12-15 1976-01-20 Geoffrey Wilkinson Hydroformylation of mono-α-olefins and mono-α-acetylenes
US3451821A (en) * 1965-03-01 1969-06-24 Kalamazoo Spice Extract Co Increasing the utilization of hops and improving flavor control of malt beverages and the like
GB1140545A (en) * 1965-03-01 1969-01-22 Kalamazoo Spice Extract Co Hop flavours for malt beverages and the like
US3536495A (en) * 1968-03-13 1970-10-27 Miller Brewing Ammonia complexes of hop alpha acids and modified alpha acids
US3720517A (en) * 1970-12-21 1973-03-13 Hamm T Brewing Co Preparation of a fermented malt champagne
GB1372932A (en) 1971-03-15 1974-11-06 Gen Foods Corp Anti-caries compositions
US3932603A (en) * 1971-05-28 1976-01-13 General Foods Corporation Oral preparations for reducing the incidence of dental caries
US3965188A (en) * 1972-01-10 1976-06-22 Miller Brewing Company Hop extract process and product
CH617326A5 (en) * 1975-12-04 1980-05-30 Siegfried Ag
US4148873A (en) * 1976-11-05 1979-04-10 S. S. Steiner, Inc. Method for treating the skin with extracts of hops
US4170638A (en) * 1976-11-05 1979-10-09 S. S. Steiner, Inc. Method for producing a deodorant
US4123561A (en) * 1977-02-01 1978-10-31 S.S. Steiner, Inc. Method for processing hops for brewing
US4401684A (en) * 1981-10-01 1983-08-30 Australian Hop Marketers Pty. Ltd. Preservation of hops utilizing ascorbic acid
US4389421A (en) * 1981-10-30 1983-06-21 Busch Industrial Products Corporation Method for controlling light stability in malt beverages and product thereof
BE896610A (en) 1982-05-06 1983-08-16 Hop Developments Ltd EXTRACTION OF PLANT MATERIAL USING CARBONIC ANHYDRIDE
US4486436A (en) 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
US4590296A (en) * 1984-01-25 1986-05-20 Miller Brewing Company Process for separation of beta-acids from extract containing alpha-acids and beta-acids
US4644084A (en) * 1984-01-25 1987-02-17 Miller Brewing Company Preparation of tetrahydroisohumulones
GB2187755B (en) 1984-02-28 1990-03-28 Kalamazoo Holdings Inc Separation of the constituents of co2 hop extracts
SU1247011A1 (en) 1985-02-20 1986-07-30 Специальное Конструкторское Бюро Химизации Научно-Производственного Объединения "Аэрозоль" Agent for hair care
DE3513169A1 (en) * 1985-04-12 1986-10-16 Hopstabil Hopfenverarbeitungs-Gesellschaft mbH, 8069 Wolnzach METHOD FOR PRODUCING ISOHUMULONES
US4767640A (en) * 1985-10-29 1988-08-30 Miller Brewing Company Light stable hop extracts and method of preparation
US4692280A (en) * 1986-12-01 1987-09-08 The United States Of America As Represented By The Secretary Of Commerce Purification of fish oils
US5041300A (en) * 1987-04-03 1991-08-20 Kalamazoo Holdings, Inc. Hop flavor which is odor forming impurity free
DE3712986A1 (en) * 1987-04-16 1988-10-27 Marbert Gmbh MEDICAL PREPARATIONS BASED ON TREASURE EXTRACT, METHOD FOR THE PRODUCTION THEREOF AND USE OF TREATMENT EXTRACT FOR THE PRODUCTION OF COSMETIC PREPARATIONS AND A SPECIAL TREATMENT EXTRACT
US4857554A (en) * 1987-08-17 1989-08-15 Georgios Kallimanis Method for the treatment of psoriasis
US5166449A (en) 1988-08-15 1992-11-24 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
US5082975A (en) * 1988-08-15 1992-01-21 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
DE3931147A1 (en) 1989-09-19 1991-03-28 Solong Natural Ltd New nerve tonic contg. extract of avena sativa - used to treat frigidity and increase libido in women
US5013571A (en) * 1990-01-31 1991-05-07 Pfizer Inc. Methods for making tetrahydroisoalpha and hexahydroisoalpha acids
EP0474892B1 (en) * 1990-09-10 1996-04-10 Fromm, Mayer-Bass Limited Process for the isomerisation of humulone in a carbon dioxide-hop extract and method for extracting the isohumulone
JP3155003B2 (en) 1990-11-06 2001-04-09 サントリー株式会社 Method for producing hop extract and hop extract obtained by the method
TW199905B (en) * 1992-02-03 1993-02-11 J E Siebel Sons Company Inc Method and composition for enhancing foam properties of fermented malt beverages
RU2045955C1 (en) 1992-02-24 1995-10-20 Никитина Татьяна Ивановна Method for treating adnexites
WO1994003192A1 (en) * 1992-07-29 1994-02-17 Drymed A/S Composition comprising fertilized shell eggs
US5286506A (en) * 1992-10-29 1994-02-15 Bio-Technical Resources Inhibition of food pathogens by hop acids
US5370863A (en) 1992-12-16 1994-12-06 Miller Brewing Company Oral care compositions containing hop acids and method
US5296637A (en) * 1992-12-31 1994-03-22 Kalamazoo Holdings, Inc. Production of odor-free tetrahydroisohumulates from alpha acids via their tetrahydrohumulates and subsequent isomerization
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
JP2677762B2 (en) * 1994-04-08 1997-11-17 株式会社神戸製鋼所 Oil-cooled compressor
EP0677289B1 (en) * 1994-04-12 1999-01-13 Hoechst Marion Roussel, Ltd. Pharmaceutical composition for treating osteoporosis
AT404469B (en) 1994-05-06 1998-11-25 Tulln Zuckerforschung Gmbh METHOD FOR THE PRESERVATION OF SUGAR-BASED PLANT EXTRACTS OR. JUICES
IN184685B (en) * 1996-02-14 2000-09-23 Nat Inst Immunology
US5827895A (en) * 1996-02-27 1998-10-27 Regents Of The University Of Minnesota Hexahydrolupulones useful as anticancer agents
US6020019A (en) * 1996-03-26 2000-02-01 Miller Brewing Company Hydrogenation of hop soft resins using CO2
US6589994B1 (en) * 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US5902816A (en) * 1997-02-21 1999-05-11 Synapse Pharmaceuticals International, Inc. Method for treatment of heavy metal poisoning
US5968539A (en) * 1997-06-04 1999-10-19 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria
MY120052A (en) 1997-09-17 2005-08-30 Honda Motor Co Ltd Lock-up control device
US6251461B1 (en) 1997-10-10 2001-06-26 S. S. Steiner, Inc. Antimicrobial activity of hops extract against Clostridium botulinum, Clostridium difficile and Helicobacter pylori
CA2321737A1 (en) 1998-03-04 1999-09-10 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid
US6224871B1 (en) * 1998-03-11 2001-05-01 Reliv International, Inc. Dietary supplement for nutritionally promoting healthy joint function
US5919813C1 (en) * 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE19841615A1 (en) 1998-09-11 2000-03-16 Fritz Armin Mueller Medicinal wine for alleviating pain and other symptoms of premenstrual syndrome, comprising mixture of extracts of different plants in dry white wine
ES2147538B1 (en) * 1999-01-29 2001-04-01 Revlon Consumer Prod Corp A CAPILLARY LOTION WITH IMPROVED PROPERTIES IN ITS HAIR PROTECTIVE AND PREVENTIVE ACTION OF HIS FALL, AND REDUCTION OF THE EXTERNAL EFFECTS OF ANDROGENETIC ALOPECIA AND WITH THAT OF THE HAIR FALL.
ZA200000857B (en) 1999-02-11 2001-05-31 Marx Anna Susan Pharmaceutical composition.
US6801860B1 (en) * 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US6462029B1 (en) * 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
US6383527B1 (en) * 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6210701B1 (en) * 1999-04-30 2001-04-03 Healthcomm International, Inc. Medical food for treating inflammation-related diseases
JP4173606B2 (en) 1999-06-18 2008-10-29 サントリー株式会社 Method for producing low acid beverage
US6129907A (en) * 1999-08-04 2000-10-10 Colgate Palmolive Company Stable hydrogenated lupulone antibacterial oral compositions
WO2001021165A1 (en) * 1999-09-21 2001-03-29 Rutgers, The State University Resveratrol analogs for prevention of disease
US6264995B1 (en) * 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
JP2001161338A (en) 1999-12-09 2001-06-19 Kyodo Shoji:Kk Method for producing sparkling liquor
US6200594B1 (en) * 1999-12-29 2001-03-13 Vital Dynamics, Inc. Breast-enhancing, herbal compositions and methods of using same
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6583322B1 (en) * 2000-02-25 2003-06-24 Kalamazoo Holdings, Inc. Dihydro and hexahydro isoalpha acids having a high ratio of trans to cis isomers, production thereof, and products containing the same
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
KR20030005252A (en) * 2000-03-31 2003-01-17 니신 오일 밀스 가부시키가이샤 External preparation for the skin and beautifying agents
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US6492429B1 (en) 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US6908630B2 (en) * 2000-08-01 2005-06-21 Metaproteomics, Llc Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2
FR2815227B1 (en) * 2000-10-17 2003-04-11 Schwartz Laboratoires Robert ANTI-STRESS COMPOSITION FOR PRIMARY INCORPORATION IN NUTRITIONAL VEHICLES
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US7078062B2 (en) * 2001-01-17 2006-07-18 S.S. Steiner, Inc. Hop-based udder and teat dips and washes
US20030035851A1 (en) * 2001-02-08 2003-02-20 Sophie Chen Anti-cancer agents and method of use thereof
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
US20030003212A1 (en) * 2001-06-13 2003-01-02 Givaudan Sa Taste modifiers
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US20040219240A1 (en) 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US8168234B2 (en) * 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7270835B2 (en) 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
EP1446136B1 (en) * 2001-10-26 2010-09-29 Metaproteomics, LLC Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20060233902A1 (en) 2002-02-14 2006-10-19 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
US7108868B2 (en) * 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US20030228369A1 (en) 2002-05-06 2003-12-11 Kuhrts Eric Hauser Process for conversion of high viscosity fluids and compositions thereof
US7144590B2 (en) * 2003-01-09 2006-12-05 Lipoprotein Technologies, Inc. Bioactive compositions derived from humulus lupulus
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US20080248131A1 (en) 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products
US20070065456A1 (en) * 2005-09-20 2007-03-22 Woods Cindy J Nutritional supplements
JP2009518439A (en) * 2005-12-09 2009-05-07 メタプロテオミクス,エルエルシー Protein kinase regulation by hops and acacia products
US8062898B2 (en) * 2006-10-20 2011-11-22 The Board Of Trustees Of The University Of Illinois Selection and rational development of solvent systems in counter-current chromatograph
FR2910325B1 (en) 2006-12-22 2010-03-19 Kronenbourg Brasseries USE OF LUPULONES FOR THE PREVENTION AND THERAPY OF COLORECTAL CANCER.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037180A2 (en) * 2002-10-21 2004-05-06 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALLATORI N. ET AL.: "Biliary Secretion of Glutathione and of Glutathione-Metal Complexes", FUNDAMENTAL AND APPLIED TOXCIOLOGY, vol. 5, 1985, pages 816 - 831, XP024876238 *
CHUNG M.J. ET AL.: "Cytotoxicity of Nitric Oxide is Alleviated by Zinc-Mediated Expression of Antioxidant Genes", EXP. BIOL. MED., vol. 231, no. 9, 2006, pages 1555 - 1563, XP008116085 *
DINKOVA-KOSTOVA ET AL.: "Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfyhydryl groups", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 6, 2001, pages 3404 - 3409, XP008116083 *
See also references of EP2152684A4 *
SINGH R.P. ET AL.: "Modulatory Influence of Andrographics paniculata on Mouse Hepatic and Extrahepatic Carcinogen Metabolizing Enzymes and Antioxidant Status", PHYTOTHER. RES., vol. 15, no. 5, 2001, pages 382 - 390, XP008116084 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307465A (en) * 2008-12-10 2012-01-04 麦特普罗泰欧米克斯有限公司 A method for the purification of substituted cyclopent-2-en-1-one congeners and substituted 1,3-cyclopentadione congeners from a complex mixture using countercurrent separation
WO2012058649A1 (en) * 2010-10-30 2012-05-03 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
US8410179B2 (en) 2010-10-30 2013-04-02 Kindex Therapeutics, Llc Cis, 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-derivatives, substantially enantiomerically pure compositions and methods
US8410178B2 (en) 2010-10-30 2013-04-02 Kindex Therapeutics, Llc CIS 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-derivatives, substantially enantiomerically pure compositions and methods
US8829056B2 (en) 2010-10-30 2014-09-09 Kindex Pharmaceuticals, Inc. Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl) cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
US9828331B2 (en) 2012-07-09 2017-11-28 Kindex Pharmaceuticals, Inc. Tetrahydro-isohumulone derivatives, methods of making and using
US10343977B2 (en) 2012-07-09 2019-07-09 Kindex Pharmaceuticals, Inc. Tetrahydro-isohumulone derivatives, methods of making and using

Also Published As

Publication number Publication date
KR20100029201A (en) 2010-03-16
US20090155382A1 (en) 2009-06-18
US20120189721A1 (en) 2012-07-26
AU2008251756B2 (en) 2013-06-06
EP2152684A4 (en) 2011-05-18
US8241674B2 (en) 2012-08-14
EP2152684A1 (en) 2010-02-17
NZ581064A (en) 2012-12-21
JP2010526882A (en) 2010-08-05
US8475850B2 (en) 2013-07-02
CN101687834A (en) 2010-03-31
AU2008251756A1 (en) 2008-11-20
CA2686043A1 (en) 2008-11-20
MX2009012087A (en) 2010-03-30

Similar Documents

Publication Publication Date Title
US8475850B2 (en) Methods and compositions for heavy metal detoxification
Kim et al. Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease
Liao et al. Cinnamaldehyde inhibits the tumor necrosis factor-α-induced expression of cell adhesion molecules in endothelial cells by suppressing NF-κB activation: Effects upon IκB and Nrf2
Zafir et al. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats
Ye et al. t-BHQ provides protection against lead neurotoxicity via Nrf2/HO-1 pathway
Liu et al. Chalcone inhibits the activation of NF-κB and STAT3 in endothelial cells via endogenous electrophile
Zhang et al. The protective role of resveratrol against arsenic trioxide-induced cardiotoxicity
Lee et al. Arylbenzofuran isolated from Dalbergia odorifera suppresses lipopolysaccharide-induced mouse BV2 microglial cell activation, which protects mouse hippocampal HT22 cells death from neuroinflammation-mediated toxicity
Rahman et al. Chemopreventive activity of glycyrrhizin on lead acetate mediated hepatic oxidative stress and its hyperproliferative activity in Wistar rats
Rios et al. Decreased nitric oxide markers and morphological changes in the brain of arsenic-exposed rats
Wan et al. Arsenic and antimony co-induced nephrotoxicity via autophagy and pyroptosis through ROS-mediated pathway in vivo and in vitro
Ohyama et al. Human gastric signet ring carcinoma (KATO-III) cell apoptosis induced by Vitex agnus-castus fruit extract through intracellular oxidative stress
Ince et al. Boron ameliorates arsenic‐induced DNA damage, proinflammatory cytokine gene expressions, oxidant/antioxidant status, and biochemical parameters in rats
Chen et al. InP/ZnS quantum dots cause inflammatory response in macrophages through endoplasmic reticulum stress and oxidative stress
Albasher et al. Effect of Moringa oleifera Lam. methanolic extract on lead-induced oxidative stress-mediated hepatic damage and inflammation in rats
Tang et al. Regulation of osteoclastogenesis by Simon extracts composed of caffeic acid and related compounds: successful suppression of bone destruction accompanied with adjuvant-induced arthritis in rats
Macedo et al. Acute carnosine administration increases respiratory chain complexes and citric acid cycle enzyme activities in cerebral cortex of young rats
Sun et al. Arsenic-induced testicular toxicity in Gallus gallus: Expressions of inflammatory cytokines and heat shock proteins
Sehonova et al. mRNA expression of antioxidant and biotransformation enzymes in zebrafish (Danio rerio) embryos after exposure to the tricyclic antidepressant amitriptyline
Liu et al. Effects of excess manganese on the oxidative status, and the expression of inflammatory factors and heat shock proteins in cock kidneys
Rouas et al. Effect of nephrotoxic treatment with gentamicin on rats chronically exposed to uranium
Zuo et al. Geniposide and geniposidic acid, modified forms of genipin, attenuate genipin-induced mitochondrial apoptosis without altering the anti-inflammatory ability in KGN cell line
Oriakhi et al. Combinatorial effect of gallic acid and catechin on some biochemical and pro-inflammatory markers in CCl4-mediated hepatic damage in rats
Sachdeva et al. Efficacy of some antioxidants supplementation in reducing oxidative stress post sodium tungstate exposure in male wistar rats
Alkharashi et al. Sulforaphane alleviates cadmium-induced toxicity in human mesenchymal stem cells through POR and TNFSF10 genes expression

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880023922.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08729724

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2686043

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008251756

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/012087

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 581064

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2010508463

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008729724

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008251756

Country of ref document: AU

Date of ref document: 20080213

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20097025967

Country of ref document: KR

Kind code of ref document: A